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A B S T R A C T
Background
Transrectal prostate biopsy (TRPB) is a well established procedure used to obtain tissue for the histological diagnosis of carcinoma of
the prostate. Despite the fact that TRPB is generally considered a safe procedure, it may be accompanied by traumatic and infective
complications, including asymptomatic bacteriuria (bacteria in the urine), urinary tract infection (UTI), transitory bacteremia (bacteria
in the blood), fever episodes, and sepsis (pathogenic microorganisms or their toxins in the blood). Although infective complications
after TRPB are well known, there is uncertainty about the necessity and effectiveness of routine prophylactic antibiotics and their
adverse effects, as well as a clear lack of standardization.
Objectives
To evaluate the effectiveness and adverse effects of prophylactic antibiotic treatment in TRPB.
Search methods
The search covered the principal electronic databases: MEDLINE, EMBASE, LILACS and the Cochrane Central Register of Controlled
Trials (CENTRAL). Experts were consulted and references from the relevant articles were scanned.
Selection criteria
All randomized, controlled trials (RCTs) of men who underwent TRPB and received prophylactic antibiotics or placebo/no treatment,
were selected, and all RCTs looking at one type of antibiotic versus another, including comparable dosages, routes of administration,
frequency of administration, and duration of antibiotic treatment.
Data collection and analysis
Two reviewers (ELZ, OACC) independently selected included trials and extracted study data. Any disagreements were resolved by a
third party (NRNJ).
Main results
Overall, more than 3500 references were considered and 19 original reports with a total of 3599 patients were included.
There were 9 trials analysing antibiotics versus placebo/no treatment, with all outcomes significantly favouring antibiotic use (P < 0.05)
(I2 = 0%), including bacteriuria (risk ratio (RR) 0.25 (95% confidence interval (CI) 0.15 to 0.42), bacteremia (RR 0.67, 95% CI
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0.49 to 0.92), fever (RR 0.39, 95% CI 0.23 to 0.64), urinary tract infection (RR 0.37, 95% CI 0.22 to 0.62), and hospitalization
(RR 0.13, 95% CI 0.03 to 0.55). Several classes of antibiotics were effective prophylactically for TRPB, while the quinolones, with the
highest number of studies (5) and patients (1188), were the best analysed. For ’antibiotics versus enema’, we analysed four studies with
a limited number of patients. The differences between groups for all outcomes were not significant. For ’antibiotic versus antibiotic +
enema’, only the risk of bacteremia (RR 0.25, 95% CI 0.08 to 0.75) was diminished in the ’antibiotic + enema group’. Seven trials
reported the effects of short-course (1 day) versus long-course (3 days) antibiotics. Long course was significantly better than short-course
treatment only for bacteriuria (RR 2.09, 95% CI 1.17 to 3.73). For ’single versus multiple dose’, there was significantly greater risk of
bacteriuria for single-dose treatment (RR 1.98, 95% CI 1.18 to 3.33). Comparing oral versus systemic administration - intramuscular
injection (IM), or intravenous (IV) - of antibiotics, there were no significant differences in the groups for bacteriuria, fever, UTI and
hospitalization.
Authors’ conclusions
Antibiotic prophylaxis is effective in preventing infectious complications following TRPB. There is no definitive data to confirm that
antibiotics for long-course (3 days) are superior to short-course treatments (1 day), or that multiple-dose treatment is superior to single-
dose.
P L A I N L A N G U A G E S U M M A R Y
Antibiotic prophylaxis for transrectal prostate biopsy
Prostate cancer is the second most commonly diagnosed cancer in men and transrectal prostate biopsy is the procedure to obtain
tissue for the histological diagnosis of carcinoma of the prostate. Despite the fact that infective complications after transrectal prostate
biopsy are well known, there is uncertainty about the necessity and effectiveness of routine prophylactic antibiotics and a clear lack of
standardization in antibiotic prophylaxis for transrectal prostate biopsy. In nine trials we observed that antibiotic prophylaxis is effective
in preventing infectious complications (bacteriuria, bacteremia, fever, urinary tract infection, sepsis) and hospitalization following
prostate biopsy. Several classes of antibiotics are effective for prophylaxis in prostate biopsy, with the quinolones the best analysed class.
There are no definitive data to confirm that antibiotic for long-course is superior to short-course treatment, or that multiple-dose
treatment is superior to single-dose treatment.
2Antibiotic prophylaxis for transrectal prostate biopsy (Review)
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B A C K G R O U N D
Description of the condition
Prostate cancer (PCa) is the second most commonly diagnosed
cancer in men and represents a significant health problem. World-
wide, more than 900,000 men are diagnosed with prostate can-
cer every year with an estimated 258,000 deaths in 2008 (Ferlay
2010). Incidence rates of prostate cancer vary by more than 25-fold
worldwide and nearly three-quarters of the registered cases occur
in economically developed countries (658,000 cases). The highest
incidence rates are in Australia/New Zealand (104.2 per 100,000),
Western and Northern Europe and North America, largely be-
cause the widespread use of prostate-specific antigen (PSA) testing
in those regions (Ferlay 2010). In these countries prostate cancer
is the most frequently diagnosed cancer among men (ACS 2010;
Ferlay 2007).
While screening - by digital rectal examination (DRE) and PSA
analysis - has increased detection of early stage prostate cancer, it
is not yet known whether early detection and subsequent treat-
ment improves disease-specific morbidity and mortality (Andriole
2009). The American Cancer Society and American Urological As-
sociation recommend annual screening (ACS 2009; AUA 2009),
while in contrast, the United States Preventive Task Force believes
that there is insufficient scientific evidence to recommend it (US
Task Force 2008).
Two recent studies evaluated the influence of screening on the
rate of death from PCa and obtained different results. The first
(Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial),
conducted in 10 centers in the United States, recruited 76,693
men who underwent PSA tests and DRE versus usual clinical
care (which could include screening for PCa) (Andriole 2009).
With 7 years of follow up, more men in the screening group were
diagnosed with PCa (7.4% versus 6.1%), but cancer mortality was
low and equal in both groups (0.13% and 0.11%). The second
study, the European Randomized Study of Screening for Prostate
Cancer (ERSPC), was conducted in 7 European countries and
included 162,243 men followed for a median of 9 years. The men
were randomized into two groups: screening (an average of once
per 4 years) versus no screening (Schröder 2009). In the screening
group the rate of PCa diagnosis was higher (8.2% versus 4.8%)
and mortality was 20% lower (0.29% versus 0.36%) relative to the
no-screening group, but at the cost of a high rate of overdiagnosis
and overtreatment.
The prostate biopsy has evolved from the digitally guided biopsy
to the current standard of the transrectal ultrasound-guided sys-
tematic biopsy (TRPB) method. The TRPB is a well established
out-patient procedure performed to obtain tissue for the histolog-
ical diagnosis of carcinoma of the prostate in men with either an
elevated, or rising, PSA, or an abnormal DRE that raises suspi-
cions of prostate cancer (Hodge 1989a; Sruogis 2005).
Description of the intervention
Despite the fact that TRPB is generally considered a safe pro-
cedure, it may be accompanied by traumatic and infective com-
plications, the latter including asymptomatic bacteriuria, urinary
tract infection, transitory bacteremia, fever episodes, and sepsis
(Crawford 1982; Isen 1999a; Aron 2000a). Although infective
complications after TRPB are well known and rarely fatal (Breslin
1978; Brewster 1993; Borer 1999), there is no agreement that their
treatment by antibiotic prophylaxis is really necessary.
There is significant variability in the reported infection rates after
TRPB. Historically, the use of larger gauge needles (14 gauge) to
perform the biopsy was associated with infection rates of 2% to
79%, but, with thinner needles, rates from 0% to 37%, irrespective
of the use of antibiotics (Aron 2000a; Fong 1991; Enlud 1997;
Roach 1991; Freitas 1999; Ruebush 1979; Shigemura 2005).
The need for prophylaxis has been questioned by several authors,
who note the incidence of post-procedural bacteremia is relatively
low, usually transient, and resolves without additional therapy (
Enlud 1997; Wendel 1967; Astraldi 1937). In one prospective
study (N = 415), patients who underwent TRPB with no antibiotic
prophylaxis had an infection complication rate of 2.9% (Enlud
1997).
Even among those who use antibiotic prophylaxis there is much
variability in the type, dose, frequency of administration, and du-
ration of treatment. Some reviews that surveyed radiology and
urology departments that regularly undertook TRPB have shown
a total of 48 different regimens utilizing 13 different antibiotics
(Taylor 1997; Shandera 1998), ranging from a single oral dose of
ciprofloxacin before TRPB, to intravenous cefuroxime and rectal
metronidazole before the procedure, followed by oral cephalexin
for 5 days.
How the intervention might work
Recent studies, including randomized, controlled trials compar-
ing the use of antibiotic versus placebo/no treatment in TRPB,
have shown that antibiotic prophylaxis results in a lower inci-
dence of post-biopsy febrile episodes, positive urine cultures, and
bacteremia (Yang 2001a; Aron 2000a; Freitas 1999; Isen 1999a;
Kapoor 1998).
Several prospective, randomized trials have examined the value of
different types of antibiotics and different regimens of antibiotic
prophylaxis in TRPB, with variable results (Cormio 2002; Petteffi
2002; Sabbagh 2004; Isen 1999a). These data confirm that there
is a clear lack of standardization in antibiotic prophylaxis for tran-
srectal prostate biopsy with widely varying costs for each of the
different regimens.
Why it is important to do this review
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The need for prophylaxis has been questioned by some authors
(Enlud 1997; Wendel 1967) and several studies included a placebo
group versus use of antibiotic (Tekdogan 2006; Wang 2004; Yang
2001a; Aron 2000a), demonstrating doubt about the effectiveness
of prophylactic antibiotics. Among studies that used antibiotic
prophylaxis there is much variability in the type, dose, frequency
of administration, and duration of treatment of antibiotics, with
conflicting results. Therefore, a systematic review is necessary to
evaluate whether antibiotic prophylaxis is necessary for TRPB, and
if so, what is the most effective and safest method.
This systematic review evaluated the effectiveness of antibiotic pro-
phylaxis in reducing the risk of infective complications following
TRPB, with no restriction of language. The review also evaluated
what should be the antibiotic of choice for prophylaxis in TRPB.
O B J E C T I V E S
The objectives of this review were:
• to evaluate the effectiveness of antibiotic prophylaxis in
reducing the risk of infective complications following TRPB
(bacteriuria, bacteremia, fever, urinary tract infection);
• to evaluate what should be the antibiotic of choice for
prophylaxis in transrectal prostate biopsy, including dosage,
route of administration, frequency of administration and
duration of treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomized, controlled trials (RCT) in which patients received
TRPB and prophylactic antibiotics versus placebo/no treatment,
and all RCTs looking at one type of antibiotic versus another,
compared dosage, route of administration, frequency of adminis-
tration, or duration of treatment.
Types of participants
Inclusion criteria
Male patients who required TRPB and received prophylactic an-
tibiotics or placebo/no treatment.
Exclusion criteria
• history of hypersensitivity to antibiotic in study
• significant gastrointestinal disease or inability to tolerate
oral medication
• presence of culture-proven urinary tract infection prior to
intervention
• presence of indwelling bladder catheters
• history of endoscopic manipulation of the urinary tract
within 7 days prior to the study enrollment
• antibiotic(s) given during the preceding 10 days
• patients with prostheses (e.g. hip replacement, prosthetic
cardiac valves) and congenital heart disease requiring
prophylactic antibiotics
Subgroups
Patients with co-morbid conditions potentially immunosuppres-
sive (and thus prone to infections), such as diabetes, renal failure,
chronic corticosteroids use, and immunodeficiency conditions.
Types of interventions
• antibiotic versus placebo or no treatment
• antibiotic class A (quinolones, sulfonamides,
aminoglycosides, cephalosporins, β-lactamase inhibitors,
metronidazole) versus class B (quinolones, sulfonamides,
aminoglycosides, cephalosporins, β-lactamase inhibitors,
metronidazole)
• single-dose versus multiple-dose treatment
• short-course (one day) versus long-course treatment (three
days)
• oral versus systemic administration (intravenous (IV) and
intramuscular (IM))
• antibiotic versus enema
Types of outcome measures
Therapeutic response according to the definition by the authors
of each study, analyzing the following variables.
1. Sepsis: SIRS caused by infection (SIRS - defined as two or
more of the following: temperature ≥ 38o C (centigrade) or less
than 36o C; heart rate more than 90 beats/minute; respiratory
rate more than 20 breaths/minute or respiratory alkalosis; white
blood cell count more than 12,000 or immature forms more
than 4000 or more than 10%) (Levy 2002)
2. Fever (temperature > 37.5o C)
3. Bacteremia: defined as the presence of bacteria in blood
culture, accessed due to protocol blood collection, irrespective of
clinical signs
4. Bacteriuria: the presence of bacteria in the urine in the post-
procedure period and/or culture proven (presence of any
uropathogen not present previously and/or colony forming units
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(CFU) > 100,000/mL) (millilitres) in the absence of clinical
signs of infection, diagnosed due to protocol urine collection
5. UTI: bacteriuria on post-procedure period associated with









2. Hospitalization due to infective complications
3. Adverse effects of antibiotics (gastrointestinal, allergic)
Search methods for identification of studies
Electronic searches
Strategies of search for electronic databases: for MEDLINE we
used the methodological search strategy for RCTs, previously re-
ported (Robinson 2002); for EMBASE we used adaptations of this
same strategy, previously reported (Lefebvre 1996); for LILACS
we used the methodological search strategy previously reported by
one of the reviewers (Castro 1999).
There was no restrictions for language.
Relevant trials were obtained from the following sources:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (Issue 1, 2008 to Issue 1,
2010);
• MEDLINE (1966 to 2010);
• EMBASE (1980 to 2010);
• LILACS (1980 to 2010).
To the methodological search strategy of each database we added
the specific terms pertinent to this review as free text and MeSH
terms.
1. methodological search strategy
2. PROSTATE/ all subheadings
3. prostat*
4. #2 or #3
5. BIOPSY/ all subheadings
6. biops*
7. #5 or #6
8. #4 and #7
9. ANTI-INFECTIVE AGENTS/ all subheadings





15. #10 or #11 or #12 or #13 or #14
16. #9 not #15





22. #16 or #17 or #18 or #19 or #20 or #21
23. #8 and #22
24. #1 and #23
25. INFECTION/ all subheadings
26. infect*
27. #25 or #26
28. #8 and #27
29. #1 and #28
30. FEVER/ all subheadings
31. pyrex*
32. #30 or #31
33. #8 and #32
34. #1 and #33
Searching other resources
• reference lists of urology textbooks, review articles and
relevant trials (All references of relevant articles were scanned and
all additional articles of potential interest were retrieved for
further analysis.)
• reference lists of abstracts from urology scientific meetings
• letters seeking information about unpublished or
incomplete trials to investigators known to be involved in
previous studies
Data collection and analysis
Selection of studies
All potential trials’ titles and abstracts were read by two reviewers
independently, and were selected for eligibility according to the
criteria specified in the protocol. Each of these articles was read
by reviewers who evaluated for inclusion. If the article did not
fit the inclusion criteria, the reasons for exclusion were detailed
(see ’Characteristics of included studies’ and ’Characteristics of
excluded studies’ tables). Any discrepancies were resolved by dis-
cussion, or by input of a third party.
Data extraction and management
For each included article a careful analysis and an attentive reading
was done to extract data. A specific formulary for data extraction
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was created and submitted to a pre-test with three studies of the
same area, but not included in this review. There was no detection
of any failure or ambiguity and the formulary was approved for
use in the major search.
Two of the reviewers independently extracted the data from the
articles (ELZ, OACC). Data were extracted on the selected clinical
outcomes, methodological characteristics, and demographics of
participants.
Assessment of risk of bias in included studies
The methodological quality of each selected trial was assessed by
the same two reviewers (ELZ, OACC). Criteria assessed were the
generation and concealment of the sequence of randomization,
blinding (investigators, participants, outcome assessors and data
analysis), intention-to-treat analysis, use of placebo, completeness
of follow up and source of funding.
Trials were assessed for methodological quality using the standard
Cochrane criteria for allocation concealment.
A - Adequate: randomization method described that does not al-
low investigator/participant to know or influence the intervention
group before an eligible participant entered into the study.
B - Unclear: randomization stated but no information on method
used is available.
C - Inadequate: method of randomization used such as alternate
medical record numbers or unsealed envelopes; any information in
the study which indicated that investigators or participants could
influence intervention group.
Only RCTs with allocation concealment classified as score A and
B were used in this review.
To assess the possibility of publication bias (Egger 2001) we per-
formed a funnel-plot test (Egger 1997).
Measures of treatment effect
For dichotomous outcome (bacteriuria, bacteremia, fever, UTI,
sepsis, hospitalization, death) results were expressed as risk ratios
(RR) with 95% confidence intervals (CI). Data were pooled using
the fixed-effects model. Heterogeneity was analysed using an I2
test (Higgins 2003). When there was considerable heterogeneity
among the studies (I2 > 50%), the random-effects model was uti-
lized. When possible, the risk difference with 95% CI was calcu-
lated for each adverse effect, either compared to no treatment . If
“considerable” heterogeneity was detected (I2 > 50%), a possible
explanation was pursued. If a reasonable cause was found, a sep-
arate analysis was performed. If the cause was not apparent and
heterogeneity was caused by divergent data in terms of direction
of results (i.e. data favouring one or other treatment), we did not
pool the data. The studies were included in a meta-analysis using
the outcomes presented above. The meta-analysis was performed
using the Review Manager 5 package. In case it was not possible
to perform a meta-analysis of the data, the results were presented
in a descriptive form with individual evaluation of the results of
each study.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
A total of 3599 men were randomized. Weighted mean age was
66.6 (14 trials), which ranged from 40 to 94 years (12 trials). Three
trials reported racial data, with 81.4% White and 11.3% Black.
Nineteen trials reported trial origination (India = 1, China = 1,
Turkey = 3, Greece = 1, Italy = 1, France = 1, United Kingdom = 3,
United States = 4, Canada = 1, Brazil = 2, multinational = 1). Study
discontinuations ranged from 0% to 25%, with an overall mean
of 4.7%. Weighted mean follow up was 13.5 days, and ranged
from 4 to 28 days.
Nine placebo controlled trials described the effects of antibiotics
versus placebo/no treatment in preventing infectious complica-
tions following TRPB (Aron 2000a; Aron 2000b; Brown 1981;
Crawford 1982; Isen 1999a; Isen 1999b; Kapoor 1998; Melekos
1990; Ruebush 1979; Tekdogan 2006; Yang 2001a; Yang 2001b).
Five trials (1229 patients) compared quinolones to placebo (Aron
2000a; Aron 2000b; Isen 1999a; Kapoor 1998; Tekdogan 2006;
Yang 2001a; Yang 2001b). Two studies compared quinolones to
nitroimidazoles (Aron 2000a and Aron 2000b = tinidazole; Yang
2001a and Yang 2001b = metronidazole). Two trials (189 pa-
tients) compared sulfonamides to placebo (Isen 1999b; Ruebush
1979). Two trials (129 patients) compared penicillins to placebo
(Melekos 1990 = piperacillin; Crawford 1982 = carbenicillin). One
trial (40 patients) compared gentamicin to placebo (Brown 1981).
The majority of trials (eight) utilized pre-biopsy enema, except
one (Ruebush 1979). Three trials were three-armed studies (Aron
2000a; Aron 2000b; Isen 1999a; Isen 1999b; Yang 2001a; Yang
2001b). One trial (Isen 1999a; Isen 1999b) compared data of two
different antibiotics versus placebo, and two trials compared an-
tibiotic short-course and long-course versus placebo (Aron 2000a;
Aron 2000b; Yang 2001a; Yang 2001b). Included patients in both
groups were low risk patients; excluded patients had predisposing
factors for infection (see ’Exclusion criteria’).
Four trials (Brown 1981; Freitas 1999; Melekos 1990; Tekdogan
2006) described the effects of antibiotics compared to enemas in
preventing infectious complications. Three trials (280 patients)
were designed to compared antibiotic versus enema versus antibi-
otic + enema versus placebo/no treatment (Brown 1981 = gentam-
icin, povidone iodine enema; Melekos 1990 = piperacillin, povi-
done iodine enema; Tekdogan 2006 = ciprofloxacin, rifampicin
enema). One trial (120 patients) (Freitas 1999) compared antibi-
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otic (ciprofloxacin) for 2 days versus antibiotic for 7 days versus
antibiotic (2 days) + enema versus enema (sodium biphosphate).
Six trials reported the effects of short-course versus long-course
antibiotics (Aron 2000a; Aron 2000b; Briffaux 2009; Cam 2008;
Petteffi 2002; Schaeffer 2007; Yang 2001a; Yang 2001b). All stud-
ies (1693 patients) compared quinolones for one day versus three
days. Five trials (1588 patients) utilized ciprofloxacin (Aron 2000a;
Aron 2000b; Briffaux 2009; Cam 2008; Schaeffer 2007 = cipro-
floxacin extended release; Yang 2001a; Yang 2001b), and in two
studies quinolones were compared to a nitroimidazole antibiotics
(Aron 2000a and Aron 2000b = tinidazole; Yang 2001a and Yang
2001b = metronidazole). One trial utilized norfloxacin (Petteffi
2002).
Seven trials reported the effects of single-dose versus multiple-
dose treatment (Aron 2000a; Aron 2000b; Bates 1998; Briffaux
2009; Cam 2008; Petteffi 2002; Schaeffer 2007; Yang 2001a;
Yang 2001b). Five trials (1588 patients) utilized ciprofloxacin (
Aron 2000a; Aron 2000b; Briffaux 2009; Cam 2008; Schaeffer
2007 = ciprofloxacin extended release; Yang 2001a; Yang 2001b),
and in two studies quinolones were compared to nitroimidazole
antibiotics (Aron 2000a and Aron 2000b = tinidazole; Yang 2001a
and Yang 2001b = metronidazole). One trial utilized norfloxacin
(Petteffi 2002) and one trial utilized co-amoxiclav (Bates 1998).
Seven trials compared different classes of antibiotics (Brewster
1995; Cam 2008; Cormio 2002; Fong 1991; Isen 1999a; Isen
1999b; Shivde 2002). We performed three subgroup analyses:
quinolones versus other antibiotics, sulfonamide versus other an-
tibiotics and piperacillin tazobactam versus other antibiotics.
Quinolones were compared to other antibiotics in three stud-
ies (648 patients) (Cam 2008 = ceftriaxone; Cormio 2002 =
piperacillin tazobactam; Isen 1999a = sulfonamide). Sulfonamide
were compared to other antibiotics in three studies (326 patients)
(Fong 1991 = netilmicin-metronidazole; Isen 1999b = ofloxacin;
Shivde 2002 = gentamicin). Piperacillin tazobactam were com-
pared to other antibiotics in two studies (247 patients) (Brewster
1995 = cefuroxime; Cormio 2002 = ciprofloxacin).
Four trials compared oral versus systemic administration with 754
patients (Cam 2008 = ceftriaxone versus ciprofloxacin; Cormio
2002 piperacillin-tazobactam versus ciprofloxacin; Fong 1991 =
netilmicin+metronidazole versus sulfonamide; Shivde 2002 = gen-
tamicin versus sulfonamide).
Results of the search
Overall, more than 3500 references were scanned and updated
to March 2010. Fifty-six were selected for full text analysis and
were retrieved. Of these, 37 were excluded for various reasons
(see ’Characteristics of excluded studies’ table). Nineteen original
reports of trials on the role of antibiotic in transrectal prostate
biopsy with a total of 3599 patients were included in the final
analysis (see the ’Characteristics of included studies’ table).
Included studies
See ’Characteristics of included studies’.
Excluded studies
Thirty seven studies were excluded (Akay 2006; Anjum 1996;
Argyropoulos 2007; Aus 1993; Aus 1996; Bjerklund 2004;
Bosquet Sanz 2006; Carey 2001; Eaton 1981; Eggert 1999;
Ferreira 1985; Herranz Amo 1996; Hosokawa 2005; Hotta 2001;
Huang 2006; Ito 2002; Janoff 2000; Jeon 2003; Khan 1984;
Lindert 2000; Lindstedt 2006; Mari 2007; Meyer 1987; Otrock
2004; Peters 2003; Puig 2006; Rees 1980; Roach 1991; Sabbagh
2004; Saleem 2001; Sharpe 1982; Shigemura 2005; Thompson
1982; Tobias-Machado 2003; Vaz 1994; Wang 2004; Yamamoto
2008). See ’Characteristics of excluded studies’ table for details.
The major causes of exclusion were:
• studies not randomized - Anjum 1996; Aus 1993; Carey
2001; Eaton 1981; Eggert 1999; Hosokawa 2005; Huang 2006;
Janoff 2000; Jeon 2003; Lindstedt 2006; Otrock 2004; Puig
2006; Rees 1980;
• inadequate randomization - Akay 2006; Hotta 2001; Roach
1991; Shigemura 2005; Tobias-Machado 2003;
• single studies of a determined intervention - Argyropoulos
2007; Ferreira 1985; Vaz 1994; Yamamoto 2008;
• lack of adequate exclusion criteria of patients - Bosquet Sanz
2006; Herranz Amo 1996; Ito 2002; Mari 2007; Meyer 1987;
Peters 2003; Sabbagh 2004; Wang 2004 (We tried to contact the
authors of these studies for more informations but to no avail.);
• different definitions of short-course and long-course
treatment than considered in review protocol - Aus 1996; Ito
2002; Mari 2007.
Risk of bias in included studies
See ’Characteristics of included studies’ table, ’Figure 1’, ’Figure 2’
and ’Summary of findings for the main comparison’, ’Summary
of findings 2’, ’Summary of findings 3’, ’Summary of findings 4’
for details.
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Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Ten of the included studies described adequate randomization
(Aron 2000a; Aron 2000b; Brewster 1995; Briffaux 2009; Cam
2008; Crawford 1982; Fong 1991; Kapoor 1998; Schaeffer 2007;
Shivde 2002; Yang 2001a; Yang 2001b) and five reported an
adequate allocation concealment (Crawford 1982; Fong 1991;
Ruebush 1979; Schaeffer 2007; Shivde 2002).
Blinding
Six trials were double blinded (Aron 2000a; Aron 2000b; Crawford
1982; Kapoor 1998; Ruebush 1979; Schaeffer 2007; Yang 2001a;
Yang 2001b)
Incomplete outcome data
All included studies apparently addressed incomplete outcome
data.
Selective reporting
All included studies were apparently free of selective reporting.
Other potential sources of bias
The majority of included studies were apparently free of other
potential sources of bias.
Ten trials were placebo controlled (Aron 2000a; Aron 2000b;
Brown 1981; Cormio 2002; Crawford 1982; Isen 1999a; Isen
1999b; Kapoor 1998; Melekos 1990; Ruebush 1979; Tekdogan
2006; Yang 2001a; Yang 2001b). A sample size was pre-planned
in two studies (Briffaux 2009; Freitas 1999). An intention-to-treat
analysis was performed in ten trials (Aron 2000a; Aron 2000b;
Briffaux 2009; Cam 2008; Cormio 2002; Crawford 1982; Freitas
1999; Kapoor 1998; Petteffi 2002; Schaeffer 2007; Yang 2001a;
Yang 2001b). Four papers referred to multicentric studies (Briffaux
2009; Kapoor 1998; Ruebush 1979; Schaeffer 2007). Three stud-
ies had industry funding (Brewster 1995; Cormio 2002; Schaeffer
2007).
Publication bias was unlikely according to the funnel plots inspec-
tion.
Effects of interventions
See: Summary of findings for the main comparison Antibiotic
compared to placebo for patients submitted to transrectal prostate
biopsy; Summary of findings 2 Short course compared to long
course treatment for patients submitted to transrectal prostate
biopsy; Summary of findings 3 Single dose compared to multiple
dose antibiotic for patients submitted to transrectal prostate
biopsy; Summary of findings 4 Oral compared to systemic
antibiotic (IM or IV) for patients submitted to transrectal prostate
biopsy
Our analysis included 19 trials with a total of 3599 patients. Not
all articles allowed data extraction for all end points (See ’Table
1’ for a more detailed description of the extractable end point of
each article and ’Table 2’ for included studies in each category of
comparison). The outcomes were analysed in each subgroup of
intervention.
Antibiotic versus placebo or no treatment
Nine trials compared antibiotic to placebo or no treatment
(Aron 2000a; Aron 2000b; Brown 1981; Crawford 1982; Isen
1999a; Isen 1999b; Kapoor 1998; Melekos 1990; Ruebush 1979;
Tekdogan 2006; Yang 2001a; Yang 2001b). The majority of tri-
als (eight) utilized pre-biopsy enema, except one (Ruebush 1979).
Three trials were three-armed studies. One trial (Isen 1999a; Isen
1999b) presented and compared data of two different antibiotics
versus placebo, and two trials presented and compared data of an-
tibiotic short-course and long-course versus placebo (Aron 2000a;
Aron 2000b; Yang 2001a; Yang 2001b).
Bacteriuria
Data on bacteriuria could be extracted from 7 trials with 870
patients (1 trial subdivided) (Brown 1981; Crawford 1982; Isen
1999a; Isen 1999b; Kapoor 1998; Melekos 1990; Ruebush 1979;
Tekdogan 2006). There were 61 events of bacteriuria among 412
patients randomized to receive placebo and 18 among 458 pa-
tients randomized to receive antibiotics. The meta-analysis was
significant and favoured antibiotic use (RR 0.25, 95% CI 0.15 to
0.42, P < 0.05). No heterogeneity was detected in the analysis (I2
= 0%) (’Figure 3’). Analysing only trials with pre-biopsy enema,
the results were similar (RR 0.28, 95% CI 0.17 to 0.46; I2 = 0%)
(’Figure 4’).
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Figure 3. Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.1 Bacteriuria.
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Figure 4. Forest plot of comparison: 1 Antibiotics (classes) versus placebo, outcome: 1.7 Bacteriuria (with
pre-biopsy enema).
Bacteremia
We collect data on bacteremia from 5 trials with 494 patients (Aron
2000a; Aron 2000b; Brown 1981; Crawford 1982; Melekos 1990;
Ruebush 1979). There were 45 events of bacteremia among 237
patients randomized to placebo and 34 events among 257 patients
randomized to receive antibiotic. The comparison was significant
and favoured antibiotic use (RR 0.67, 95% CI 0.49 to 0.92, P
< 0.05) (I2 = 40%) (’Figure 5’). Analysing only trials with pre-
biopsy enema, the results also favoured antibiotics (RR 0.44, 95%
CI 0.22 to 0.87 ;I2 = 32%) (’Figure 6’).
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Figure 5. Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.2 Bacteremia.
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Figure 6. Forest plot of comparison: 1 Antibiotics (classes) versus placebo, outcome: 1.8 Bacteremia (with
pre-biopsy enema).
Fever
Data on fever was extracted from 7 trials with 820 patients (Aron
2000a; Aron 2000b; Brown 1981; Crawford 1982; Melekos 1990;
Ruebush 1979; Tekdogan 2006; Yang 2001a; Yang 2001b). There
were 43 events of fever among 397 patients randomized to placebo
and 17 among 423 patients randomized to receive antibiotic. The
comparison was significant and favoured antibiotic use (RR 0.39,
95% CI 0.23 to 0.64). No heterogeneity was detected in the anal-
ysis (I2 = 0%) (’Figure 7’). Analysing only trials with pre-biopsy
enema, the results were similar and favoured antibiotics (RR 0.34,
95% CI 0.20 to 0.61). No heterogeneity was detected (I2 = 0%)
(’Figure 8’).
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Figure 7. Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.3 Fever.
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We collected data on UTI from 3 trials with 1077 patients (Aron
2000a; Aron 2000b; Kapoor 1998; Yang 2001a; Yang 2001b).
There were 48 events among 534 patients randomized to placebo,
and 18 among 543 randomized to receive antibiotic. The meta-
analysis was significant and favoured antibiotics (RR 0.37, 95%
CI 0.22 to 0.62). No heterogeneity was detected in the analysis (I
2 = 0%). All trials used pre-biopsy enemas.
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Figure 9. Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.4 UTI.
Sepsis
This endpoint was reported in only one study (Crawford 1982).
There were 3 events of sepsis among 25 patients randomized to
placebo and 1 event among 23 randomized to antibiotic use (RR
0.36, 95% CI 0.04 to 3.24).
Hospitalization
(’Figure 10’)
Data on hospitalization could be collect from 2 trials (1 trial subdi-
vided) with 650 patients (Isen 1999a; Isen 1999b; Kapoor 1998).
There were 10 hospitalizations among the 306 patients random-
ized to placebo and only 1 among the 344 patients randomized
to antibiotics. The comparison was significant and favoured an-
tibiotics (RR 0.13, 95% CI 0.03 to 0.55). No heterogeneity was
detected (I2 = 0%). All trials used pre-biopsy enemas.
Figure 10. Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.5 Hospitalization.
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Adverse effects
(’Figure 11’)
This endpoint (nausea and abdominal cramps in Crawford 1982,
pruritis and diarrhea in Ruebush 1979) was poorly reported among
the included studies, and was extracted from only two studies with
127 patients. The comparison was not significant (RR 1.62, 95%
CI 0.23 to 11.56), and no heterogeneity was detected (I2 = 0%).
Figure 11. Forest plot of comparison: 1 Antibiotic (classes) versus placebo, outcome: 1.6 Adverse events.
Mortality




Three trials were included with 628 patients (Isen 1999a; Kapoor
1998; Tekdogan 2006); the meta-analysis favoured quinolones
(RR 0.33, 95% CI 0.17 to 0.64; I2 = 0%).
Bacteremia
(’Figure 5’)
One trial was included (Aron 2000a; Aron 2000b), with two sub-
groups (antibiotic short-course and long-course) with 306 pa-
tients. The comparison between the groups (quinolones versus




Three trials (Aron 2000a; Aron 2000b; Tekdogan 2006; Yang
2001a; Yang 2001b) (two with subgroups) were included with
640 patients. The comparison between the groups (quinolones x
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Three trials were included (Aron 2000a; Aron 2000b; Kapoor
1998;Yang 2001a; Yang 2001b) with 1077 patients; the compar-




Two trials were included with 582 patients (Isen 1999a; Kapoor





Two studies were included with 133 patients (Isen 1999b; Ruebush
1979) and use of sulfonamide lowered risk relative to placebo (RR
0.17, 95% CI 0.05 to 0.57; I2 = 0%); only one trial (Ruebush
1979) reported data for bacteremia (26 events in 37 patients in
the placebo group versus 25 events in 42 antibiotic patients (RR
0.85 95% CI 0.61 to 1.17), fever (5 events in 33 in the placebo
group versus 4 in 38 patients in antibiotic group (RR 0.69 CI
0.20 to 2.38) and adverse events (1 in 37 in placebo versus 1 in
42 in antibiotic group (RR 0.88 95% CI 0.06 to 13.59) and only
one trial reported data for hospitalization (Isen 1999b) (3 events
among 23 randomized to placebo versus 0 in 45 randomized to
antibiotic (RR 0.07, 95% CI 0.00 to 1.38).
Other classes of antibiotics (except quinolones and
sulfonamides)
The outcomes analysed were bacteriuria, bacteremia and fever. For
adverse events only one trial reported (Crawford 1982). There was
1 event among 23 patients randomized to antibiotic use (diarrhea,




Three studies were included with 109 patients (Brown 1981;
Crawford 1982; Melekos 1990) and favoured antibiotic use (RR
0.20, 95% CI 0.07 to 0.54; I2 = 0%).
Bacteremia
(’Figure 5’)
Three studies were included with 109 patients (Brown 1981;
Crawford 1982; Melekos 1990). The comparison was significant
and favoured “other classes” (RR 0.47, 95% CI 0.22 to 0.98,
P < 0.05), but with considerable heterogeneity (I2 = 63%). The
heterogeneity is caused by one trial (Crawford 1982), but the
reason was not apparent. We then re-analysed the data utilizing
random effects, but heterogeneity was still 63%. By eliminating
Crawford we eliminated the heterogeneity (fixed effect RR 0.20,
95% CI 0.06 to 0.62; I2 = 0%).
Fever
(’Figure 7’)
Three studies were included with 109 patients (Brown 1981;
Crawford 1982; Melekos 1990). Use of antibiotics lowered risk of
fever (RR 0.23, 95% CI 0.10 to 0.54; I2 = 0%).
Antibiotic versus enema
Antibiotic was compared with enema in four studies (Brown 1981;
Freitas 1999; Melekos 1990; Tekdogan 2006).
Bacteriuria
(’Figure 12’)
Data on bacteriuria were extracted from 3 trials with 139 pa-
tients (Brown 1981; Melekos 1990; Tekdogan 2006). There were
5 events of bacteriuria among 68 patients randomized to enema
and 9 among 71 randomized to receive antibiotic. The compar-
ison between the groups was not significant (RR 1.71, 95% CI
0.61 to 4.79; I2 = 0%).
Figure 12. Forest plot of comparison: 2 Antibiotic versus Enema, outcome: 2.1 Bacteriuria.
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Bacteremia
(’Figure 13’)
Data on bacteremia were collected from 2 trials with 60 pa-
tients (Brown 1981; Melekos 1990). There were 5 events of bac-
teremia among 28 patients randomized to enema and 11 among
32 randomized to receive antibiotics. The comparison between
the groups was not significant (RR 1.89, 95% CI 0.40 to 8.93) (I2
= 61%) using a random-effects model. There was no explicit cause
for the heterogeneity, and the limited number of studies made a
sensitivity analysis unviable.
Figure 13. Forest plot of comparison: 2 Antibiotic versus Enema, outcome: 2.2 Bacteremia.
Fever
(’Figure 14’)
Four trials with 197 patients reported data on fever (Brown 1981;
Freitas 1999; Melekos 1990; Tekdogan 2006). There were 15
events of fever among 96 patients randomized to enema and 10
among 101 randomized to receive antibiotic. The comparison be-
tween groups was not significant (RR 0.89, 95% CI 0.16 to 5.05)
(I2 = 66%) using a random-effects model. No apparent cause was
identified for the heterogeneity and a sensitivity analysis was not
viable due to the limited number of studies.
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Figure 14. Forest plot of comparison: 2 Antibiotic versus Enema, outcome: 2.3 Fever.
UTI, sepsis and hospitalization
These endpoints were reported in only one study (Freitas 1999).
There were 11 events of UTI among 28 patients randomized to
enema versus 2 events among 30 randomized to antibiotic use (RR
0.17, 95% CI 0.04 to 0.70); 2 events of sepsis and 2 events of
hospitalization in 28 patients in the group taking enemas versus 0
events in the antibiotic group (P > 0.05).
Antibiotic versus antibiotic + enema
This intervention was reported for four trials (Brown 1981; Freitas
1999; Melekos 1990; Tekdogan 2006).
Bacteriuria
(’Figure 15’)
Figure 15. Forest plot of comparison: 3 Antibiotic versus Antibiotic + Enema, outcome: 3.1 Bacteriuria.
Data on bacteriuria were extracted from 3 trials with 147 pa-
tients (Brown 1981; Melekos 1990; Tekdogan 2006). There were
9 events of bacteriuria among 71 patients randomized to antibi-
otic and 4 among 76 randomized to receive antibiotic + enema.
The comparison between the groups was not significant (RR 0.42,
95% CI 0.13 to 1.29; I2 = 0%).
Bacteremia
(’Figure 16’)
Data on bacteremia were collected from 2 trials with 68 patients
(Brown 1981; Melekos 1990). There were 11 events of bacteremia
among 32 patients randomized to antibiotic and 3 among 36
randomized to receive antibiotic + enema. Combination therapy
lowered risk relative to monotherapy (RR 0.25, 95% CI 0.08 to
0.75; I2 = 0%).
24Antibiotic prophylaxis for transrectal prostate biopsy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 16. Forest plot of comparison: 3 Antibiotic versus Antibiotic + Enema, outcome: 3.2 Bacteremia.
Fever
(’Figure 17’)
Data on fever were collected from 4 trials with 209 patients (Brown
1981; Freitas 1999; Melekos 1990; Tekdogan 2006). There were
10 events of fever among 101 patients randomized to enema and
5 among 108 randomized to receive antibiotic. The comparison
between the groups was not significant (RR 0.53, 95% CI 0.21 to
1.34; I2 = 38%).
Figure 17. Forest plot of comparison: 3 Antibiotic versus antibiotic + enema, outcome: 3.3 Fever.
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Short-course (one day) versus long-course treatment
(three days)
This intervention was reported in six trials (Aron 2000a; Cam
2008; Briffaux 2009; Petteffi 2002; Schaeffer 2007; Yang 2001a).
Bacteriuria
(’Figure 18’)
Data on bacteriuria were extracted from 3 trials with 869 patients
(Briffaux 2009; Petteffi 2002; Schaeffer 2007). There were 32
events of bacteriuria among 428 patients randomized to short-
course treatment and 16 among 441 randomized to long-course
treatment. The comparison favoured long-course treatment (RR
2.09, 95% CI 1.17 to 3.73; I2 = 34%).
Figure 18. Forest plot of comparison: 4 Short-course treatment versus long-course treatment, outcome:
4.1 Bacteriuria.
Bacteremia
Data on bacteremia were collected from 1 trial with 156 patients
(Aron 2000a). There was no events among 79 patients randomized
to short-course treatment and 1 among 77 randomized to long-
course treatment (RR 0.33, 95% CI 0.01 to 7.86).
Fever
(’Figure 19’)
Data on fever were collected from 4 trials with 652 patients (Aron
2000a; Cam 2008; Petteffi 2002; Yang 2001a). There were 12
events of fever among 324 patients randomized to short-course
treatment and 4 among 328 randomized to long-course treatment.
The comparison between the groups was not significant (RR 2.84,
95% CI 0.99 to 8.16), and with no heterogeneity (I2 = 0%).
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From 5 trials that included 1312 patients were collected data on
UTI (Aron 2000a; Briffaux 2009; Cam 2008; Schaeffer 2007;
Yang 2001a). There were 21 events of UTI among 651 patients
randomized to short-course treatment and 15 among 661 ran-
domized to long-course treatment. The comparison between the
groups was not significant (RR 1.40, 95% CI 0.73 to 2.68) and
no heterogeneity was detected (I2 = 0%).




Data on hospitalization was extracted from 2 trials with 366 pa-
tients (Cam 2008; Petteffi 2002). There were 3 events among 181
patients randomized to short-course treatment and 0 among 185
randomized to long-course treatment. The comparison between
the groups was not significant (RR 4.14, 95% CI 0.47 to 36.46)
and with no heterogeneity (I2 = 0%).
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Figure 21. Forest plot of comparison: 4 Short-course treatment versus long-course treatment, outcome:
4.5 Hospitalization.
Single dose versus multiple dose treatment
This intervention was reported in 7 trials (Aron 2000a; Bates 1998;




We were able to collect data on bacteriuria from 4 trials with
944 patients (Bates 1998; Briffaux 2009; Petteffi 2002; Schaeffer
2007). There were 38 events among 465 patients randomized to
single-dose treatment and 20 among 479 randomized to multi-
ple-dose treatment. The comparison favoured multiple-dose treat-
ment (RR 1.98; 95% CI 1.18 to 3.33) (I2 = 7%).
Figure 22. Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.1 Bacteriuria.
Bacteremia
Data on bacteremia could be extracted from 1 trial with 156 pa-
tients (Aron 2000a). There were no events among 79 patients ran-
domized to single-dose treatment and 1 among 77 of those ran-




28Antibiotic prophylaxis for transrectal prostate biopsy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We collected data on fever from 4 trials with 652 patients (Aron
2000a; Cam 2008; Petteffi 2002; Yang 2001a). There were 12
events among 324 patients randomized to single-dose treatment
and 4 among 328 of those randomized to multiple-dose treatment.
The comparison between the groups was not significant (RR 2.84,
95% CI 0.0.99 to 8.16) and with no heterogeneity (I2 = 0%).
Figure 23. Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.3 Fever.
Urinary tract infection
(’Figure 24’)
Data on UTI was extracted from 5 trials with 1312 patients (Aron
2000a; Briffaux 2009; Cam 2008; Schaeffer 2007; Yang 2001a).
There were 21 events among 651 patients randomized to single-
dose treatment and 15 among 661 of those randomized to multi-
ple-dose treatment. The comparison between the groups was not
significant (RR 1.40, 95% CI 0.73 to 2.68), and no heterogeneity
(I2 = 0%).
Figure 24. Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.4 UTI.
29Antibiotic prophylaxis for transrectal prostate biopsy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sepsis
This endpoint was reported in only one study (Bates 1998). There
were 2 events of sepsis among 37 patients in single dose group




Data on hospitalization was collected from 3 trials with 441 pa-
tients (Bates 1998; Cam 2008; Petteffi 2002). There were 5 hos-
pitalizations among 218 patients randomized to single-dose treat-
ment and 1 among those 223 patients randomized to multiple-
dose treatment. The comparison between the groups was not sig-
nificant (RR 3.10, 95% CI 0.64 to 15.06), and no heterogeneity
was detected (I2 = 0%).
Figure 25. Forest plot of comparison: 5 Multiple dose versus single dose, outcome: 5.5 Hospitalization.
Antibiotic class A versus B
Included in this section were studies that compared different types
of antibiotics, subdivided into classes of antibiotics. We performed
three subgroup analyses: quinolone versus other antibiotics; sul-
fonamide versus other antibiotics; and piperacillin tazobactam ver-
sus other antibiotics.
Quinolones versus other antibiotics
The outcomes analysed were bacteriuria, fever, UTI, sepsis and
hospitalization. The comparisons between the groups (quinolone
and other antibiotics) were not significant for all outcomes.
Bacteriuria
(’Figure 26’)
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Figure 26. Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.1
Bacteriuria.
Two trials with 225 patients (Cormio 2002; Isen 1999a) compared
quinolone versus sulfonamide and quinolone versus piperacillin
tazobactam (RR 0.93, 95% CI 0.28 to 3.10); no heterogeneity
was detected (I2 = 0%).
Fever
(’Figure 27’)
Figure 27. Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.3 Fever.
31Antibiotic prophylaxis for transrectal prostate biopsy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Two trials ( Cormio 2002; Cam 2008) with 561 patients com-
pared quinolone versus piperacillin tazobactam and ceftriaxone




Figure 28. Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.4 UTI.
Two trials with 407 patients compared quinolone versus
piperacillin-tazobactam and ceftriaxone (Cormio 2002; Cam
2008) (RR 0.72, 95% CI 0.18 to 2.88). Moderate heterogeneity
was detected (I2 = 25%).
Sepsis
This endpoint was reported in only one study (Cormio 2002).
There was one event among 66 randomized to quinolone and 0
events in group piperacillin/tazobactam (P > 0.05)
Hospitalization
(’Figure 29’)
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Figure 29. Forest plot of comparison: 6 Quinolones versus other classes of antibiotics, outcome: 6.5
Hospitalization.
Two trials with 407 patients (Cam 2008; Cormio 2002) com-
pared quinolone versus piperacillin-tazobactam and ceftriaxone
(RR 0.56, 95% CI 0.07 to 4.16); no heterogeneity was detected
(I2 = 0%).
Sulfonamide versus other antibiotics
The outcomes analysed were bacteriuria, bacteremia and UTI. For
bacteriuria (’Figure 30’), three trials were included (Fong 1991;
Isen 1999a; Shivde 2002) with 303 patients comparing sulfon-
amide to gentamicin, netilmicin-metronidazole and quinolone.
There were 5 events among 161 patients using sulfonamide and 15
events among 142 randomized to other antibiotics. The compar-
ison between these groups was not significant (RR 3.10, 95% CI
0.60 to 16.13; I2 = 53%), using a random-effects model. There was
no apparent reason for heterogeneity. Bacteremia and UTI were
reported in only one study (Fong 1991). There were 13 events of
bacteremia and 2 events of UTI among 47 patients randomized to
the netilmicin-metronidazole group and 20 events of bacteremia
and 0 events of UTI among 54 randomized to sulfonamide (P >
0.05).
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Figure 30. Forest plot of comparison: 7 Sulfonamides versus other antibiotics, outcome: 7.1 Bacteriuria.
Piperacillin tazobactam versus other antibiotics
The outcomes analysed were bacteriuria, bacteremia, fever, UTI,
sepsis, hospitalization and adverse events.
For bacteriuria, UTI, sepsis and hospitalization, two trials were
included (Brewster 1995; Cormio 2002) with 247 patients. The
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Figure 31. Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.1
Bacteriuria.




Figure 32. Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.2 UTI.
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The risk ratio was 1.01, 95% CI 0.32 to 3.15, but with hetero-
geneity (I2 = 44%).
Sepsis
(’Figure 33’)
Figure 33. Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.3
Sepsis.
The risk ratio was 3.10, 95% CI 0.33 to 29.40, and no hetero-
geneity (I2 = 0%).
Hospitalization
(’Figure 34’)
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Figure 34. Forest plot of comparison: 8 Piperacillin tazobactam versus other antibiotics, outcome: 8.4
Hospitalization.
The RR was 3.10, 95% CI 0.33 to 29.40, P > 0.05, and no
heterogeneity was detected (I2 = 0%).
For bacteremia and adverse events only one trial reported (Brewster
1995). There were 0 events of bacteremia and 16 adverse events
(diarrhea) among 54 patients randomized to piperacillin-tazobac-
tam (P < 0.05) and 1 event of bacteremia (P > 0.05) and 2 of
adverse events (diarrhea) among 55 randomized to cefuroxime (P
< 0.05); fever was reported in one trial (Cormio 2002). There was
1 event of fever among 66 patients randomized to quinolone and
0 events in 72 patients randomized to piperacillin-tazobactam (P
> 0.05)
Oral versus systemic administration
The outcomes analysed were bacteriuria, fever, UTI and hospital-
ization. Bacteremia and sepsis were reported in only one study and
meta-analysis was not realized. There were 13 events of bacteremia
among 47 patients randomized to systemic antibiotic versus 20
events of bacteremia among 54 randomized to oral antibiotic (P >
0.05) (Fong 1991). There was 1 event of sepsis among 66 patients
randomized to oral antibiotic versus 0 events among 72 random-
ized to systemic antibiotic (P > 0.05) (Cormio 2002).
Bacteriuria
(’Figure 35’)
Data on bacteriuria was extracted from 3 trials with 354 patients
(Cormio 2002; Fong 1991; Shivde 2002). There were 5 events of
bacteriuria among 182 patients randomized to oral treatment and
15 among 172 randomized to systemic treatment. The comparison
between groups was not significant (RR 0.34, 95% CI 0.06 to
1.93; I2 = 58%, using the random-effects model). There was no
explicit cause to justify heterogeneity.
Figure 35. Forest plot of comparison: 9 Oral versus systemic antibiotic administration, outcome: 9.1
Bacteriuria.
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Fever
(’Figure 36’)
Data on fever was collected from 3 trials with 522 patients (Cam
2008; Cormio 2002; Shivde 2002). There were 2 events of bac-
teriuria among 258 patients randomized to oral treatment and 1
among 264 randomized to systemic treatment. The comparison
between the groups was not significant (RR 1.80, 95% CI 0.24 to
13.45). No heterogeneity was detected (I2 = 0%).
Figure 36. Forest plot of comparison: 9 Oral versus systemic antibiotic administration, outcome: 9.2 Fever.
UTI
(’Figure 37’)
We collected data on UTI from 3 trials with 508 patients (Cam
2008; Cormio 2002; Fong 1991). There were 4 events of UTI
among 250 patients randomized to oral treatment and 5 among
258 randomized to systemic treatment. The comparison between
the groups was not significant (RR 0.85, 95% CI 0.27 to 2.70).
Heterogeneity was detected (I2 = 22%).
Figure 37. Forest plot of comparison: 9 Oral versus systemic antibiotic administration, outcome: 9.3 UTI.
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Hospitalization
(’Figure 38’)
Data on hospitalization was extracted from 2 trials with 407 pa-
tients (Cam 2008; Cormio 2002). There were 2 events of hospi-
talization among 196 patients randomized to oral treatment and
1 among 211 randomized to systemic treatment. The comparison
between the groups was not significant (RR 1.80, 95% CI 0.24 to
13.45). No heterogeneity was detected (I2 = 0%).
Figure 38. Forest plot of comparison: 9 Oral versus Systemic antibiotic administration, outcome: 9.4
Hospitalization.
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D I S C U S S I O N
Summary of main results
This systematic review addressed the totality of the evidence for
antibiotic prophylaxis for transrectal prostate biopsy. The results
favoured the use of antibiotics in transrectal prostate biopsy to
prevent infectious complications. In the analysis antibiotic versus
placebo/no treatment, all outcomes significantly favored antibi-
otics versus placebo. Nine trials compared antibiotic to placebo
or no treatment, and eight trialsutilized pre-biopsy enemas. These
results confirm the necessity of antibiotic prophylaxis for transrec-
tal prostate biopsy and emphasize substantial infection and hospi-
talization rates without antibiotic prophylaxis (bacteriuria 14.8%
without antibiotics versus 3.9% with antibiotics; bacteremia 8.6%
versus 2.1%; fever 10.8% versus 4.0%; UTI 9.0% versus 3.3%;
hospitalization 3.3% versus 0.3%) (see ’Summary of findings for
the main comparison’).
Analysing the different classes of antibiotics versus placebo/no
treatment, in the quinolones group the results favoured the use
of antibiotics to prevent bacteriuria, UTI and hospitalization, and
there was a tendency toward fever reduction as well; in ’other an-
tibiotics’, the use of antibiotics prevented bacteriuria and fever. In
analysing studies that directly compared different classes of an-
tibiotics, there was no difference between quinolones and ’other
classes of antibiotics’ (sulfonamides, piperacillin tazobactam and
ceftriaxone). Comparing sulfonamide to ’other classes of antibi-
otics’ and comparing piperacillin tazobactam with ’other antibi-
otics’, there were no differences for any outcome. The quinolones
were the most analysed, with the largest number of patients and
trials included, and therefore indicate the best evidence for the use
of antibiotic prophylaxis for prostate biopsy.
For ’antibiotic versus enema and antibiotic versus antibiotic +
enema’, only four trials were analysed, with a limited number of
patients. The difference between the groups was not significant
for any outcome, and all had some heterogeneity. In the analysis
’antibiotic versus antibiotic + enema’, only the risk of bacteremia
was diminished for the group antibiotic + enema, and with no
differences in the outcomes for bacteriuria and fever.
Comparing ’antibiotic short-course versus long-course’, there was
a significant difference favouring long-course treatment only for
bacteriuria. For bacteremia, fever, UTI and hospitalization, the
differences between the groups were not significant. (see ’Summary
of findings 2’).
For the analysis ’multiple-dose versus single-dose treatment’ there
was a significant reduction only in the risk of bacteriuria with the
multiple-dose treatment arm; for the outcome fever, the compari-
son favoured the multiple-dose treatment arm, but it was not sig-
nificant (P = 0.06). (see ’Summary of findings 3’).
Comparing the different ways of administering antibiotics (oral
versus systemic), the comparisons were not significant for bacteri-
uria, fever, UTI and hospitalization (see ’Summary of findings 4’).
Overall completeness and applicability of
evidence
The information provided by this review are relevant and fairly
robust, especially regarding effectiveness of antibiotic prophylaxis
in reducing the risk of infective complications following TRPB in
low risk patients (see ’Exclusion criteria’). Regarding what should
be the antibiotic of choice for prophylaxis in TRPB, the data
are insufficient to confirm that antibiotic use for long course is
superior to short course or that multiple-dose is superior to single-
dose treatment.
Quality of the evidence
For the analysis antibiotic versus placebo/no treatment, the qual-
ity of the evidence was moderate, especially due to unclear allo-
cation concealment and lack of blinding in several studies. Nine
studies were included (see ’Summary of findings for the main
comparison’).
For the analysis antibiotic short-course versus long-course six trials
were included. The quality of the evidence was moderate, espe-
cially due to unclear allocation concealment in several studies, with
good numbers of patients and no heterogeneity (see ’Summary of
findings 2’).
For the analysis ’multiple-dose versus single-dose treatment’ the
quality of the evidence is moderate to low, specially due unclear al-
location concealment and wide confidence interval in several stud-
ies, with good numbers of patients and no heterogeneity. Seven
trials were included (see ’Summary of findings 3’).
For ’antibiotic versus enema’ and ’antibiotic versus antibiotic +
enema’, the quality of the evidence is poor because of a limited
number of studies (4), patients and events.
Potential biases in the review process
This systematic review probably identified all relevant studies and
all relevant data about interventions and outcomes could be ob-
tained. The methods used for review process were rigorous and
probably free of bias.
Agreements and disagreements with other
studies or reviews
A systematic review of literature (Bootsma 2008) was conducted
to address antibiotic prophylaxis in urologic procedures, and
included articles searched in the electronic databases MED-
LINE, EMBASE and The Cochrane Library, and with some lan-
guage restrictions (English, French, Spanish, German). Only the
transurethral resection of the prostate and prostate biopsy sections
were well researched and had a high and moderate-to-high level
of evidence, respectively, in favour of using antibiotic prophylaxis.
The authors presented a narrative review, without meta-analysis,
and the results were presented in a descriptive form. They showed
a significant decrease of bacteriuria after prostate biopsy with the
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use of antibiotic prophylaxis compared to no use of antibiotics
(moderate to high evidence); nevertheless, no conclusive evidence
was found regarding the effect of antibiotic prophylaxis on symp-
tomatic UTIs and other infectious complications.
A meta-analysis of antibiotic prophylaxis use in transrectal pro-
static biopsy was published recently (Yang 2009), but examined
only English and Chinese medical literature. Twelve trials with
1987 patients were included (Melekos 1990; Fong 1991; Brewster
1995; Aus 1996; Kapoor 1998; Isen 1999a; Aron 2000a; Yang
2001a; Cormio 2002; Petteffi 2002; Tobias-Machado 2003; Akay
2006). The authors proposed to compare an antibiotic-treated
group versus a control group with the outcomes bacteriuria, bac-
teremia and fever. In the methodology section the control group
was defined as “receiving placebo or no agent”; however, included
in this group were studies comparing two different types of antibi-
otics (Fong 1991; Cormio 2002; Tobias-Machado 2003), studies
comparing antibiotic short course versus long course (Aus 1996;
Petteffi 2002; Tobias-Machado 2003), and all without placebo
comparators. Therefore, the authors “created” a control group
that was not completely a no treatment or placebo group. There
were also two studies with inadequate randomization (Akay 2006;
Tobias-Machado 2003). Yang’s use of poor methodology resulted
in limited validity, and should be consulted with caution.
Compared to the two reviews presented above, our systematic
review is wider ranging, by comparing not only antibiotics to
placebo, but also comparing different classes of antibiotics, doses,
and duration of treatment.
The sextant biopsy scheme significantly improved cancer detec-
tion over digitally directed biopsy of palpable nodules and ultra-
sound-guided biopsy of specific hypoechoic lesions (Hodge 1989a;
Hodge 1989b) and remained the gold standard for several years.
Numerous groups have published series showing improved cancer
detection rates by incorporating additional laterally directed cores
into the standard systematic sextant technique, ultimately taking
anywhere from 8 to 13 cores (Eskew 1997; Naughton 2000a;
Babaian 2000; Presti 2000). At present, the six-cores scheme is
considered inadequate for routine prostate biopsy for cancer de-
tection because it may miss over 20% of cancers. Extended biopsy
protocols do not result in increased complications compared to
sextant biopsy (Mariappan 2004; Naughton 2000b; Naughton
2001; Paul 2004; Paul 2005).
Many of the studies included in this analysis are from when 6-core
biopsies were standard. Currently, 12 to 16 core biopsies are being
performed. Nevertheless, as discussed above, extended biopsy pro-
tocols do not result in increased complications compared to sex-
tant biopsy technique. There was no randomized controlled study
comparing different antibiotics regimens for different number of
cores on biopsy.
The rule of saturation biopsy is most often applied to patients with
previous negative biopsies and patients who have been diagnosed
with prostate cancer and remain on active surveillance protocols
or are considering focal therapy (Jones 2006). The safety and ef-
ficacy of saturation biopsy has been well established, but further
studies are needed to validate these strategies over extended biopsy
schemes (Patel 2009). Complications with saturation biopsy were
similar to extended biopsy technique.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Antibiotic prophylaxis is effective in preventing infectious com-
plications following prostate biopsy. Several classes of antibiotics
are effective for prophylaxis in prostate biopsy and the quinolones
was the best analysed class, with higher numbers of studies and
patients. There is no definitive data to confirm that antibiotic use
for long course (3 days) is superior to antibiotic for short course
(1 day), or that multiple-dose is superior to single-dose treatment.
There is no significant difference between different ways of ad-
ministering antibiotics (oral versus IM or IV) to prevent infectious
complications.
Implications for research
Following these results, it is unlikely that future trials will fea-
ture a no-treatment control group for antibiotic prophylaxis in
prostate biopsy. Trials comparing different classes of antibiotics,
short-course versus long-course treatment and multiple-dose ver-
sus single-dose treatment are necessary to confirm or deny our
findings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aron 2000a
Methods randomized, double-blinded, placebo-controlled trial
Participants 231 male adults submitted to TRPB
Interventions antibiotic for 1 day (Ciprofloxacin 500 mg orally + tinidazole 600 mg orally single dose)
or antibiotic for 3 days (ciprofloxacin 500 mg orally 12/12h 3d + Tinidazole 600 mg
orally 12/12h 3d) (with enema) or placebo
Outcomes bacteremia, fever, UTI, infectious complications
Notes exclusion criteria: bleeding diathesis, UTI, immunosuppressed patients, heart disease,
indwelling catheter
TCI: urine cultures (48 hours), blood cultures (if fever)
Fever: 38o C
digitally directed TRPB; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Patients were randomized into three
groups, using computer-generated random
numbers.”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk Double-blinded study. “Patients in group
1 . . . received a placebo tablet twice a day
for 3 days, . . . In group 2, 79 patients .
. were given a single dose of ciprofloxacin
(500 mg) and tinidazole (600 mg) orally at
the same time, followed by placebo tablet
twice a day for five more doses. In group 3,
77 patients . . were given the same combi-
nation and dose but for 3 days.”
Incomplete outcome data addressed?
All outcomes
Low risk “No patient was excluded from the study
after randomization”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
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Aron 2000b
Methods randomized, double-blinded, placebo-controlled trial
Participants 231 male adults submitted to TRPB
Interventions antibiotic for 1 day (ciprofloxacin 500 mg orally + tinidazole 600 mg orally single dose)
or antibiotic for 3 days (ciprofloxacin 500 mg orally 12/12h 3d + tinidazole 600 mg
orally 12/12h 3d) (with enema) or placebo
Outcomes bacteremia, fever, UTI, infectious complications
Notes exclusion criteria: bleeding diathesis, UTI, immunosuppressed patients, heart disease,
indwelling catheter
TCI: urine cultures (48 hours), blood cultures (if fever)
Fever: 38o C
digitally directed TRPB; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “patients were randomized into three
groups, using computer-generated random
numbers.”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk Double-blinded study. “Patients in group
1 . . received a placebo tablet twice a day
for 3 days, . . . In group 2, 79 patients . .
. were given a single dose of ciprofloxacin
(500 mg) and tinidazole (600 mg) orally at
the same time, followed by placebo tablet
twice a day for five more doses. In group 3,
77 patients . . were given the same combi-
nation and dose but for 3 days.”
Incomplete outcome data addressed?
All outcomes
Low risk “No patient was excluded from the study
after randomization”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
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Bates 1998
Methods randomized controlled trial
Participants 75 male adults submitted to TRPB
Interventions antibiotic single dose (co-amoxiclav 1.2 g IV) or antibiotic multiple dose (co-amoxiclav
1.2g IV + co-amoxiclav 250/125 mg orally 8/8h 1 day) (with enema)
Outcomes bacteriuria, sepsis, hospitalization
Notes exclusion criteria: UTI, prostatitis, indwelling catheter, DM, steroid therapy, heart valves,
penicillin hypersensibility, immunosuppression
TCI: urine sample 72 h after biopsy
Fever: >37.5o C
UTI: 100.000 UFC/mL
mean of four biopsy cores (2 to 6); 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were then randomized to receive”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk “Eight patients (four from each group) were found to have
asymptomatic UTIs . . . ; these patients were excluded
from the study”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Brewster 1995
Methods randomized controlled trial
Participants 111 male adults submitted to TRPB
Interventions antibiotic (cefuroxime 1.5g IV single dose) or another antibiotic (piperacillin/tazobactam
4.5g IV single dose) (with enema)
Outcomes bacteriuria, bacteremia, UTI, sepsis, hospitalization, adverse events
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Brewster 1995 (Continued)
Notes exclusion: penicillin hypersensibility, heart valve, heart murmur, rectal stenosis, concur-
rent ATB therapy, bleeding diathesis, anticoagulant therapy
TCI: urine and blood cultures (after 48h)
Fever: > ou = 37.5o C
UTI: 100.000 UFC/mL
four biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “One-hundred and eleven eligible consecutive patients
were randomized to receive ....”
Information provided by author: “utilized randomising
card system”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk Patients were not told which drug they were given
Incomplete outcome data addressed?
All outcomes
Low risk “Of the 111 men in the study, 109 men were evaluable:
one patient receiving cefuroxime failed to complete all the
temperature assessments in his diary card and one patient
receiving PT did not provide the 48h MSU and blood
culture sample”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Comment: Apparently free
Briffaux 2009
Methods randomized controlled trial
Participants 288 male adult submitted to TRPB
Interventions antibiotic for 1 day (2 Ciprofloxacin 500 mg tablets orally single dose) or antibiotic for
3 days (2 Ciprofloxacin 500 mg tablets orally + ciprofloxacin 500 mg orally 12/12h 3d)
Outcomes bacteriuria, UTI
Notes exclusion: allergy, risk factors for infection (diabetes, immunosuppression, urinary stent)
, ATB use in the previous week, active UTI, valvular heart disease
TCI: urine culture, blood cell count
UTI: 10.000 UFC/mL
at least 10 biopsy cores; 18 gauge needle
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Briffaux 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “patients were randomized by a permutation block”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk “Analysis was planned in an intention-to-treat basis”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Comment: Apparently free
Brown 1981
Methods randomized, placebo-controlled trial
Participants 40 male adults submitted to TRPB
Interventions antibiotic (Gentamicin 80mg IM single dose) or enema (povidone-iodine) or ATB +
enema or placebo (saline clean enema)
Outcomes bacteriuria, bacteremia, fever
Notes exclusion: use of ATB or urologic manipulation 24h before, positive urine or blood
culture, marked general debility, valvular heart disease, valvular prostheses
TCI: urine and blood cultures
Fever: > 101 F (38.3o C)
UTI: > 100.000 UFC/mL
2 to 4 biopsy cores (mean 2.7); 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were randomized into one of four
groups”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk Not blinded
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Brown 1981 (Continued)
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Unclear risk Imprecision - few patients and few events
Cam 2008
Methods randomized controlled trial
Participants 400 male adults submitted to TRPB
Interventions antibiotic short course (ceftriaxone 1g IM single dose) or antibiotic short course (cipro-
floxacin 500 mg orally single dose) or antibiotic long course (ciprofloxacin 500 mg orally
12/12h 3d) (without enema)
Outcomes fever, UTI, hospitalization
Notes exclusion: UTI, use of ATB
TCI: urine culture
fever: > 38.0o C
12 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The patients were prospectively randomized in three
groups”
Information provided by author: “utilized a computer
program that assigned each subsequent patient into a
group”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
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Cormio 2002
Methods randomized controlled trial
Participants 138 male adults submitted to TRPB
Interventions antibiotic (piperacillin/tazobactam 2250 mg IM 12/12h 2d) or another antibiotic (ci-
profloxacin 500 mg orally 12/12h 7d) (with enema)
Outcomes bacteriuria, fever, ITU, sepsis, hospitalization




6-12 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients scheduled for TPB at our unit were randomized
to receive”




High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk “Six patients (two in Group 1 and four in Group 2) were
excluded because of positive urine cultures before TPB”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Crawford 1982
Methods randomized, double-blinded, placebo-controlled trial
Participants 48 male adults submitted to TRPB
Interventions Antibiotic (carbenicillin 2 tablets orally 6/6h 1d) or placebo (with enema)
Outcomes bacteriuria, bacteremia, fever, sepsis
Notes exclusion: UTI, prosthetic devices, rheumatic valvular heart disease, allergy to penicillin,
use of ATB (14 day before)
TCI: urine culture (24h before, 48h and 2 weeks after biopsy) and blood cultures (15
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1 to 6 biopsy cores
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Patients were assigned randomly to receive
the treatment drug . . or a placebo”
Information provided by author: used a
random generator for sequence generation
Allocation concealment? Low risk Information provided by author: “Used a
random generator”; “the study nurse let in-




Low risk “Patients were assigned randomly to receive
the treatment drug (carbenicillin indanyl
sodium) or a placebo that was indistin-
guishable from the study drug”
Information provided by author: investiga-
tors and patients were blinded
Incomplete outcome data addressed?
All outcomes
Low risk “Of 63 patients entered into the study 15
were considered nonevaluable”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Fong 1991
Methods randomized controlled trial
Participants 101 male adults submitted to TRPB
Interventions ATB (netilmicin 1.5mg/Kg IV + metronidazole 500 mg orally - single dose) or another
ATB (trimethoprim/sulfo methoxazole 320mg/1600mg orally - single dose) (with en-
ema)
Outcomes bacteriuria, symptomatic UTI, bacteremia
Notes exclusion: allergy to drug treatment, severe constipation, indwelling catheter, antibiotic
change, vomiting, failure to take the medication
TCI: blood and urine culture
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2-3 biopsy cores; 14 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Randomization was done by pre-selection from a table
of number for regimens A and B”
Allocation concealment? Low risk “pre-selection from a table of number for regimens A and




High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk “Of these patients 16 (14%) were excluded from the study:
11 in group 1 and 5 in group 2”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Freitas 1999
Methods randomized controlled trial
Participants 120 male adults submitted to TRPB
Interventions enema (sodium biphosphate) or ATB (Ciprofloxacin 500mg 12/12h 2d) or ATB long
course (ciprofloxacin 500 mg 12/12h 7d) or ATB + enema
Outcomes bacteriuria, fever, sepsis, mortality, hospitalization





6 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
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Freitas 1999 (Continued)
Adequate sequence generation? Unclear risk The patients were divided, randomly, into four groups
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Isen 1999a
Methods randomized, placebo-controlled trial
Participants 110 male patients submitted to TRPB
Interventions ATB (Ofloxacin 400 mg orally single dose) or ATB (trimethoprim/sulfonamide methox-
azole 160 mg/800 mg orally single dose) or placebo (with enema)
Outcomes bacteriuria, hospitalization
Notes exclusion: artificial heart valve, indwelling catheter, diabetes, steroid use, prostatitis, ATB
use 72h before
TCI: urine culture
6 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were randomly divided into 3 groups”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Unclear risk No information provided
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
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Isen 1999a (Continued)
Free of other bias? Unclear risk Randomization resulted in 23, 42 and 45 pa-
tients in the three groups
Isen 1999b
Methods randomized, placebo-controlled trial
Participants 110 male patients submitted to TRPB
Interventions ATB (ofloxacin 400 mg orally single dose) or ATB (trimethoprim/sulfonamide methox-
azole 160 mg/800 mg orally single dose) or placebo (with enema)
Outcomes bacteriuria, hospitalization
Notes exclusion: artificial heart valve, indwelling catheter, diabetes, steroid use, prostatitis, ATB
use 72h before
TCI: urine culture
6 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were randomly divided into 3 groups”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Unclear risk No information provided
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Unclear risk The randomization result in 23, 42 and 45 pa-
tients in the three groups
Kapoor 1998
Methods randomized, double-blinded, placebo-controlled trial
Participants 537 male adult submitted to TRPB
Interventions Antibiotic (ciprofloxacin 500 mg orally single dose) or placebo (with enema)
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Kapoor 1998 (Continued)
Outcomes bacteriuria, bacteremia, fever, UTI, sepsis, hospitalization, adverse events
Notes exclusion: hypersensibility to ciprofloxacin, valvular heart disease, significant gastroin-
testinal disease, epilepsy, bacteriuria, urologic manipulation, indwelling catheter, ATB
use (7d), granulocyte count < 1000/mm3
TCI: urine culture, urinalysis
Fever: 37.5o C
UTI: 10.000 UFC/mL
4 biopsy cores; 18 or 20 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “This was a prospective, randomized, dou-
ble-blind, placebo controlled trial . . . ;
Those patients who met enrollment crite-
ria were assigned in a 1:1 ratio to one of the
two treatment groups in accordance with a
computer-generated randomization sched-
ule.”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk “a prospective, randomized, double-
blinded, placebo-controlled trial”
Incomplete outcome data addressed?
All outcomes
Low risk “Five hundred thirty-seven patients . . .
comprised the safety (intent-to-treat) pop-
ulation”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Melekos 1990
Methods randomized, placebo-controlled trial
Participants 81 male adults submitted to TRPB
Interventions antibiotic (piperacillin 2 g IV single dose) or enema (PVPI) or ATB + enema
Outcomes bacteriuria, bacteremia, fever
Notes exclusion: general debility, heart disease, UTI, use of ATB 24 prior, urologic manipula-
tion
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Melekos 1990 (Continued)
TCI: MSU culture, blood culture
Fever: 38.5o C
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were randomized into one of the fol-
lowing four groups”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk Not blinded
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Petteffi 2002
Methods randomized controlled trial
Participants 105 male adults submitted to TRPB
Interventions Antibiotic short-course (norfloxacin 400mg orally single dose) or antibiotic long-course
(norfloxacin 400 mg orally 12/12h for 3 days) (with enema)
Outcomes bacteriuria, fever, hospitalization
Notes exclusion criteria: allergy to norfloxacin, indwelling catheter, chronic or within less than
30 days of ATB use, leucopenia, valvular cardiac conditions or valvular prosthesis, fac-
tors that could potentially interfere in the analysis results: diabetes, neoplasty, AIDS,
corticosteroids use
TCI: blood count, urine culture
UTI: 100.000 UFC/mL
12 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “patients randomly separated in two groups”
Allocation concealment? Unclear risk No information provided
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Low risk “A clinical trial, simple-blind, controlled”
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Ruebush 1979
Methods randomized, double-blind, placebo-controlled trial
Participants 79 male patients submitted to TRPB
Interventions ATB (trimethoprim/sulfonamide metoxazole 40/200 mg orally 12/12h 7d) or placebo
(no enema)
Outcomes bacteriuria, bacteremia, fever
Notes exclusion criteria: valvular heart disease, intravascular prosthesis, fever, use of ATB during
the week before
TCI: urine culture (1d before, 2-4 hours after biopsy, 7-14 days later); blood cultures
(before, during and 15 to 25 minutes after final)
Fever: 37.6o C
UTI: 10.000 UFC/mL
1 to 7 biopsy cores
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Each patient was assigned randomly to
a coded bottle containing 16 tablets of a
combination”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk “Each patient was assigned randomly to
a coded bottle containing 16 tablets of a
combination of 40 mg. trimethoprim and
200 mg. sulfamethoxazole or a placebo that
was identical in appearance”
Incomplete outcome data addressed?
All outcomes
Low risk “Nine patients were excluded from analysis
for the following reasons”
66Antibiotic prophylaxis for transrectal prostate biopsy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ruebush 1979 (Continued)
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Schaeffer 2007
Methods randomized, double-blind, controlled trial
Participants 497 male adults submitted to TRPB
Interventions Antibiotic 1day or 3 days (ciprofloxacin extended-release 1000 mg 1x/d) (with enema)
Outcomes bacteriuria, UTI
Notes exclusion criteria: MSU positive (>10000 UFC), hypersensitivity to quinolone, valvular
heart disease, renal or hepatic insufficiency, CNS disorder that might predispose do
seizures, endoscopic manipulation of urinary tract in last 7 days, indwelling catheter
within 48 hours, ATB within 7 days
TCI: urine culture, blood culture (if fever)
UTI: 10.000 UFC/mL
mean of 9.3 and 9.5 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “patients were randomized to receive oral
ciprofloxacin”
Information provided by author: “The ran-
domization was 1:1, with a block size of 4”
Allocation concealment? Low risk Information provided by author: “sealed
code break envelopes will be provided to
the investigator with each shipment of
study medication”; “Study personnel di-
rectly involved in the conduct of the study




Low risk “For patients in the 1-day arm the first and
third doses of ciprofloxacin XR were re-
placed with placebo.”
Incomplete outcome data addressed?
All outcomes
Low risk intention-to-treat analysis. “The ’enrolled’
population consisted of all patients enrolled
in the study, including those who received
no study medication”
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Schaeffer 2007 (Continued)
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Shivde 2002
Methods randomized controlled trial
Participants 115 male adults submitted to TRPB
Interventions antibiotic (trimethoprim 200 mg orally 2 doses) or another antibiotic (gentamicin 120
mg IV single dose) (without enema)
Outcomes bacteriuria, fever
Notes exclusion criteria: valvular heart diseases and protheses, symptomatic UTI, drug sensi-
tivities, diabetes
TCI: urine sample, urine culture
UTI: 100.000 UFC/mL
4 to 6 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The patients recruited in this study were randomised to
receive”
Contact with author: “we employed the ’Blocked ran-
domisation’ process”
Allocation concealment? Low risk Contact with author: “employed central randomisation”;
“The procedure was carried out by specialist registrars
working with the respective consultants and hence the Se-
nior Registrar, the other main investigators were blinded




Low risk blinded evaluators, but not patients
Incomplete outcome data addressed?
All outcomes
Low risk “a total of 128 patients were enrolled in the trial but only
115 were available for the final analysis”
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
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Tekdogan 2006
Methods randomized, placebo-controlled trial
Participants 159 male adults submitted to TRPB
Interventions Antibiotic (ciprofloxacin 1000 mg/d 4d) or enema (rifampicin) or enema + ATB or none
treatment
Outcomes bacteriuria, fever
Notes exclusion criteria: previous prostatic biopsy or prostatic surgery, diabetes, abnormal blood
leukocyte counts, neurogenic disease with voiding dysfunction, valvular heart disease,
UTI, catheterization in last 15 days, any antibiotic - anticoagulant - immunosuppressive
treatment
TCI: MSU culture 2 days after biopsy, blood culture (if fever)
Fever: 38o C
UTI: 100.000 UFC/mL
6 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Patients were randomized into four groups.”
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
High risk No blinded
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
Yang 2001a
Methods randomized, blinded, placebo-controlled trial
Participants 192 male adults submitted to TRPB
Interventions ATB short course (ciprofloxacin 500 mg orally + metronidazole 400 mg orally single
dose) or ATB long course (ciprofloxacin 500 mg orally 12/12h + metronidazole 400 mg
orally 12/12h 3d) or placebo (with enema)
Outcomes fever, UTI
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Yang 2001a (Continued)
Notes exclusion criteria: coagulation disturbance, acute infectious disease, severe cardiac disease
TCI: urine culture, blood culture (if fever)
Fever: 38o C
UTI: 100.000 UFC/mL
13 biopsy cores; 18 gauge needle
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Patients were randomly divided into three
groups by computer generated sequence
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk Group A received placebo orally 2/day for
3 days; group B received ciprofloxacin and
metronidazole 1x and other 5x were given
oral placebo; group C received ciprofloxa-
cin and metronidazole 2x/day for 3 days
Incomplete outcome data addressed?
All outcomes
Low risk all patients analysed analysed
Free of selective reporting? Low risk apparently free
Free of other bias? Low risk apparently free
Yang 2001b
Methods a randomized, blinded, placebo-controlled trial
Participants 192 male adults submitted to TRPB
Interventions ATB short course (Ciprofloxaxin 500 mg orally + Metronidazole 400 mg orally single
dose) or ATB long course (ciprofloxacin 500 mg orally 12/12 hours + metronidazole
400 mg orally 12/12 hours/3 days) or placebo (with enema)
Outcomes fever, UTI
Notes exclusion criteria: coagulation disturbance, acute infectious disease, severe cardiac disease
TCI: urine culture, blood culture (if fever)
Fever: 38o C
UTI: 100.000 UFC/mL
13 biopsy cores; 18 gauge needle
Risk of bias
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Yang 2001b (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Patients were randomly divided into three
groups by computer-generated sequence
Allocation concealment? Unclear risk No information provided
Blinding?
All outcomes
Low risk Group A received placebo orally 2x/day for
3 days; group B received ciprofloxacin and
metronidazole 1x and other 5x were given
oral placebo; group C received ciprofloxa-
cin and metronidazole 2x/day for 3 days
Incomplete outcome data addressed?
All outcomes
Low risk All patients analysed
Free of selective reporting? Low risk Apparently free
Free of other bias? Low risk Apparently free
TCI: tests of control of infection. TRPB: transrectal prostate biopsy. ATB: antibiotic. UTI: urine tract infection. DM: diabetes. CNS:
central nervous system.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akay 2006 inadequate randomization - the patients were divided into two groups according to their order of arrival
Anjum 1996 not randomized
Argyropoulos 2007 single study comparing time of administration of antibiotic making impossible the realization of meta-
analysis
Aus 1993 not randomized
Aus 1996 short-course antibiotic versus long-course antibiotic, but long-course so long (7 days) - the review protocol
considered long-course as 3 days
Bjerklund 2004 doesn’t have patients and interventions of interest
Bosquet Sanz 2006 without exclusion criteria of patients - we tried to contact the authors but to no avail
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(Continued)
Carey 2001 not randomized - retrospective study
Eaton 1981 case report
Eggert 1999 not randomized
Ferreira 1985 single study comparing local and systemic administration of antibiotic making impossible realization of
meta-analysis
Herranz Amo 1996 without adequate exclusion criteria of patients (included patients with co-morbidities and with urinary
catheter)
Hosokawa 2005 not randomized
Hotta 2001 inadequate randomization determined by preference of the urologist
Huang 2006 retrospective study
Ito 2002 without exclusion criteria of patients; short-course antibiotic versus long-course antibiotic, but short-course
so long (3 days), that was considered long-course in the protocol review
Janoff 2000 retrospective study
Jeon 2003 retrospective study
Khan 1984 doesn’t have patients and interventions of interest
Lindert 2000 not randomized
Lindstedt 2006 not randomized
Mari 2007 without exclusion criteria of patients (except UTI); short-course antibiotic versus long-course antibiotic,
but long-course so long (5 days)
Meyer 1987 without exclusion criteria of patients - we tried to contact the authors but to no avail
Otrock 2004 retrospective study
Peters 2003 without exclusion criteria of patients - we tried to contact the authors but to no avail
Puig 2006 retrospective study
Rees 1980 not randomized
Roach 1991 inadequate randomization - by alternation
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(Continued)
Sabbagh 2004 without adequate exclusion criteria of patients (no urinalysis taken prior to the procedure) - we tried to
contact the authors but to no avail
Saleem 2001 doesn’t have intervention of interest
Sharpe 1982 doesn’t have patients and interventions of interest
Shigemura 2005 inadequate randomization by alternation
Thompson 1982 not randomized- don’t have patients and interventions of interest
Tobias-Machado 2003 inadequate randomization - only the groups of interventions were randomized, but patients were not
randomized
Vaz 1994 single study comparing lomefloxacin versus lomefloxacin plus metronidazole
Wang 2004 without exclusion criteria of patients - we tried to contact the authors but to no avail
Yamamoto 2008 single study comparing trovafloxacin versus levofloxacin
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics (classes) versus placebo




participants Statistical method Effect size
1 Bacteriuria 8 870 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.15, 0.42]
1.1 Quinolones 3 628 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.17, 0.64]
1.2 Sulfonamides 2 133 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.05, 0.57]
1.3 Other classes of antibiotics 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.07, 0.54]
2 Bacteremia 6 494 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.49, 0.92]
2.1 Quinolones 2 306 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.05, 2.01]
2.2 Sulfonamides 1 79 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.61, 1.17]
2.3 Other classes of antibiotics 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.22, 0.98]
3 Fever 9 820 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.23, 0.64]
3.1 Quinolones 5 640 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.22, 1.06]
3.2 Sulfonamides 1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.20, 2.38]
3.3 Other classes of antibiotics 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.10, 0.54]
4 UTI 5 1077 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.22, 0.62]
4.1 Quinolones 5 1077 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.22, 0.62]
5 Hospitalization 3 650 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.03, 0.55]
5.1 Quinolones 2 582 Risk Ratio (M-H, Fixed, 95% CI) 0.16 [0.03, 0.87]
5.2 Sulfonamides 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.38]
6 Adverse events 2 127 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.23, 11.56]
6.1 Sulfonamides 1 79 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.06, 13.59]
6.2 Other classes of antibiotics 1 48 Risk Ratio (M-H, Fixed, 95% CI) 3.25 [0.14, 76.01]
7 Bacteriuria (with pre-biopsy
enema)
7 805 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.17, 0.46]
7.1 Quinolones 3 628 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.17, 0.64]
7.2 Sulfonamides 1 68 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.07, 0.93]
7.3 Other classes of antibiotics 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.07, 0.54]
8 Bacteremia (with pre-biopsy
enema)
5 415 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.22, 0.87]
8.1 Quinolones 2 306 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.05, 2.01]
8.2 Other classes of antibiotics 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.22, 0.98]
9 Fever (with pre-biopsy enema) 8 749 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.20, 0.61]
9.1 Quinolones 5 640 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.22, 1.06]
9.2 Other classes of antibiotics 3 109 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.10, 0.54]
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Comparison 2. Antibiotics versus enema




participants Statistical method Effect size
1 Bacteriuria 3 139 Risk Ratio (M-H, Fixed, 95% CI) 1.71 [0.61, 4.79]
2 Bacteremia 2 60 Risk Ratio (M-H, Random, 95% CI) 1.89 [0.40, 8.93]
3 Fever 4 197 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.16, 5.05]
Comparison 3. Antibiotics versus antibiotics + enema




participants Statistical method Effect size
1 Bacteriuria 3 147 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.13, 1.29]
2 Bacteremia 2 68 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.08, 0.75]
3 Fever 4 209 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.21, 1.34]
Comparison 4. Short-course versus long-course treatment




participants Statistical method Effect size
1 Bacteriuria 3 869 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [1.17, 3.73]
2 Fever 4 652 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [0.99, 8.16]
3 UTI 5 1312 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.73, 2.68]
4 Hospitalization 2 366 Risk Ratio (M-H, Fixed, 95% CI) 4.14 [0.47, 36.46]
Comparison 5. Single versus multiple dose




participants Statistical method Effect size
1 Bacteriuria 4 944 Risk Ratio (M-H, Fixed, 95% CI) 1.98 [1.18, 3.33]
2 Fever 4 652 Risk Ratio (M-H, Fixed, 95% CI) 2.84 [0.99, 8.16]
3 UTI 5 1312 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.73, 2.68]
4 Hospitalization 3 441 Risk Ratio (M-H, Fixed, 95% CI) 3.10 [0.64, 15.06]
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Comparison 6. Quinolones versus other classes of antibiotics




participants Statistical method Effect size
1 Bacteriuria 2 225 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.28, 3.10]
1.1 Sulfonamides 1 87 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.25, 7.97]
1.2 Piperacillin Tazobactam 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.11, 3.54]
2 Fever 2 407 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.07, 4.16]
2.1 Piperacillin Tazobactam 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.38]
2.2 Ceftriaxone 1 269 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.06, 14.80]
3 UTI 2 407 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.18, 2.88]
3.1 Piperacillin Tazobactam 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 3.75]
3.2 Ceftriaxone 1 269 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.24, 8.26]
4 Hospitalization 2 407 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.07, 4.16]
4.1 Ceftriaxone 1 269 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.06, 14.80]
4.2 Piperacillin Tazobactam 1 138 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.38]
Comparison 7. Sulfonamides versus other antibiotics




participants Statistical method Effect size
1 Bacteriuria 3 303 Risk Ratio (M-H, Random, 95% CI) 3.10 [0.60, 16.13]
1.1 Gentamicin 1 115 Risk Ratio (M-H, Random, 95% CI) 5.85 [0.71, 48.51]
1.2 Netilmicin-metronidazole 1 101 Risk Ratio (M-H, Random, 95% CI) 9.19 [1.19, 70.81]
1.3 Quinolone 1 87 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.13, 4.07]
Comparison 8. Piperacillin tazobactam versus other antibiotics




participants Statistical method Effect size
1 Bacteriuria 2 247 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.31, 3.46]
1.1 Cefuroxime 1 109 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.11, 3.76]
1.2 Ciprofloxacin 1 138 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.28, 9.49]
2 UTI 2 247 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.32, 3.15]
2.1 Cefuroxime 1 109 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.15, 2.34]
2.2 Ciprofloxacin 1 138 Risk Ratio (M-H, Fixed, 95% CI) 5.45 [0.27, 111.43]
3 Sepsis 2 247 Risk Ratio (M-H, Fixed, 95% CI) 3.10 [0.33, 29.40]
3.1 Cefuroxime 1 109 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.12, 70.77]
3.2 Ciprofloxacin 1 138 Risk Ratio (M-H, Fixed, 95% CI) 3.27 [0.14, 78.87]
4 Hospitalization 2 247 Risk Ratio (M-H, Fixed, 95% CI) 3.10 [0.33, 29.40]
4.1 Cefuroxime 1 109 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.12, 70.77]
4.2 Ciprofloxacin 1 138 Risk Ratio (M-H, Fixed, 95% CI) 3.27 [0.14, 78.87]
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Comparison 9. Oral versus systemic antibiotic administration (IM or IV)




participants Statistical method Effect size
1 Bacteriuria 3 354 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.06, 1.93]
2 Fever 3 522 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.24, 13.45]
3 UTI 3 508 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.27, 2.70]
4 Hospitalization 2 407 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [0.24, 13.45]
Analysis 1.1. Comparison 1 Antibiotics (classes) versus placebo, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 1 Bacteriuria
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Isen 1999a 2/42 6/23 11.8 % 0.18 [ 0.04, 0.83 ]
Kapoor 1998 7/241 21/242 31.8 % 0.33 [ 0.14, 0.77 ]
Tekdogan 2006 2/40 3/40 4.5 % 0.67 [ 0.12, 3.78 ]
Subtotal (95% CI) 323 305 48.1 % 0.33 [ 0.17, 0.64 ]
Total events: 11 (Antibiotics), 30 (Placebo)
Heterogeneity: Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
2 Sulfonamides
Ruebush 1979 0/31 7/34 10.9 % 0.07 [ 0.00, 1.23 ]
Isen 1999b 3/45 6/23 12.0 % 0.26 [ 0.07, 0.93 ]
Subtotal (95% CI) 76 57 22.9 % 0.17 [ 0.05, 0.57 ]
Total events: 3 (Antibiotics), 13 (Placebo)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.87 (P = 0.0041)
3 Other classes of antibiotics
Melekos 1990 1/25 5/16 9.2 % 0.13 [ 0.02, 1.00 ]
Brown 1981 1/11 4/9 6.7 % 0.20 [ 0.03, 1.52 ]
Crawford 1982 2/23 9/25 13.1 % 0.24 [ 0.06, 1.00 ]
Subtotal (95% CI) 59 50 29.0 % 0.20 [ 0.07, 0.54 ]
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 4 (Antibiotics), 18 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Total (95% CI) 458 412 100.0 % 0.25 [ 0.15, 0.42 ]
Total events: 18 (Antibiotics), 61 (Placebo)
Heterogeneity: Chi2 = 3.02, df = 7 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 5.38 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
Analysis 1.2. Comparison 1 Antibiotics (classes) versus placebo, Outcome 2 Bacteremia.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 2 Bacteremia
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Aron 2000a 0/79 2/75 5.2 % 0.19 [ 0.01, 3.89 ]
Aron 2000b 1/77 2/75 4.1 % 0.49 [ 0.05, 5.26 ]
Subtotal (95% CI) 156 150 9.4 % 0.32 [ 0.05, 2.01 ]
Total events: 1 (Antibiotics), 4 (Placebo)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Sulfonamides
Ruebush 1979 25/42 26/37 56.6 % 0.85 [ 0.61, 1.17 ]
Subtotal (95% CI) 42 37 56.6 % 0.85 [ 0.61, 1.17 ]
Total events: 25 (Antibiotics), 26 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
3 Other classes of antibiotics
Brown 1981 2/11 5/9 11.3 % 0.33 [ 0.08, 1.30 ]
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
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(. . . Continued)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crawford 1982 5/23 4/25 7.8 % 1.36 [ 0.41, 4.45 ]
Melekos 1990 1/25 6/16 15.0 % 0.11 [ 0.01, 0.81 ]
Subtotal (95% CI) 59 50 34.1 % 0.47 [ 0.22, 0.98 ]
Total events: 8 (Antibiotics), 15 (Placebo)
Heterogeneity: Chi2 = 5.41, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 257 237 100.0 % 0.67 [ 0.49, 0.92 ]
Total events: 34 (Antibiotics), 45 (Placebo)
Heterogeneity: Chi2 = 8.33, df = 5 (P = 0.14); I2 =40%
Test for overall effect: Z = 2.48 (P = 0.013)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
Analysis 1.3. Comparison 1 Antibiotics (classes) versus placebo, Outcome 3 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 3 Fever
Study or subgroup antibiotics placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Aron 2000a 2/79 5/75 11.2 % 0.38 [ 0.08, 1.90 ]
Aron 2000b 2/77 5/75 11.1 % 0.39 [ 0.08, 1.95 ]
Tekdogan 2006 3/40 2/40 4.4 % 1.50 [ 0.26, 8.50 ]
Yang 2001a 1/64 3/62 6.7 % 0.32 [ 0.03, 3.02 ]
Yang 2001b 1/66 3/62 6.8 % 0.31 [ 0.03, 2.93 ]
Subtotal (95% CI) 326 314 40.2 % 0.48 [ 0.22, 1.06 ]
Total events: 9 (antibiotics), 18 (placebo)
Heterogeneity: Chi2 = 2.06, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
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(. . . Continued)
Study or subgroup antibiotics placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Sulfonamides
Ruebush 1979 4/38 5/33 11.7 % 0.69 [ 0.20, 2.38 ]
Subtotal (95% CI) 38 33 11.7 % 0.69 [ 0.20, 2.38 ]
Total events: 4 (antibiotics), 5 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
3 Other classes of antibiotics
Brown 1981 0/11 3/9 8.4 % 0.12 [ 0.01, 2.04 ]
Crawford 1982 4/23 12/25 25.2 % 0.36 [ 0.14, 0.97 ]
Melekos 1990 0/25 5/16 14.6 % 0.06 [ 0.00, 1.01 ]
Subtotal (95% CI) 59 50 48.1 % 0.23 [ 0.10, 0.54 ]
Total events: 4 (antibiotics), 20 (placebo)
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00074)
Total (95% CI) 423 397 100.0 % 0.39 [ 0.23, 0.64 ]
Total events: 17 (antibiotics), 43 (placebo)
Heterogeneity: Chi2 = 5.64, df = 8 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 3.65 (P = 0.00027)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
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Analysis 1.4. Comparison 1 Antibiotics (classes) versus placebo, Outcome 4 UTI.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 4 UTI
Study or subgroup antibiotics placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Aron 2000a 4/79 14/75 29.5 % 0.27 [ 0.09, 0.79 ]
Aron 2000b 6/77 14/75 29.1 % 0.42 [ 0.17, 1.03 ]
Kapoor 1998 6/257 12/260 24.5 % 0.51 [ 0.19, 1.33 ]
Yang 2001a 1/64 4/62 8.3 % 0.24 [ 0.03, 2.11 ]
Yang 2001b 1/66 4/62 8.5 % 0.23 [ 0.03, 2.04 ]
Total (95% CI) 543 534 100.0 % 0.37 [ 0.22, 0.62 ]
Total events: 18 (antibiotics), 48 (placebo)
Heterogeneity: Chi2 = 1.12, df = 4 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 3.77 (P = 0.00016)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
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Analysis 1.5. Comparison 1 Antibiotics (classes) versus placebo, Outcome 5 Hospitalization.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 5 Hospitalization
Study or subgroup antibiotics placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Isen 1999a 0/42 3/23 34.4 % 0.08 [ 0.00, 1.48 ]
Kapoor 1998 1/257 4/260 30.4 % 0.25 [ 0.03, 2.25 ]
Subtotal (95% CI) 299 283 64.8 % 0.16 [ 0.03, 0.87 ]
Total events: 1 (antibiotics), 7 (placebo)
Heterogeneity: Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.12 (P = 0.034)
2 Sulfonamides
Isen 1999b 0/45 3/23 35.2 % 0.07 [ 0.00, 1.38 ]
Subtotal (95% CI) 45 23 35.2 % 0.07 [ 0.00, 1.38 ]
Total events: 0 (antibiotics), 3 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Total (95% CI) 344 306 100.0 % 0.13 [ 0.03, 0.55 ]
Total events: 1 (antibiotics), 10 (placebo)
Heterogeneity: Chi2 = 0.60, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.77 (P = 0.0056)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
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Analysis 1.6. Comparison 1 Antibiotics (classes) versus placebo, Outcome 6 Adverse events.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 6 Adverse events
Study or subgroup antibiotics placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Sulfonamides
Ruebush 1979 1/42 1/37 68.9 % 0.88 [ 0.06, 13.59 ]
Subtotal (95% CI) 42 37 68.9 % 0.88 [ 0.06, 13.59 ]
Total events: 1 (antibiotics), 1 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 Other classes of antibiotics
Crawford 1982 1/23 0/25 31.1 % 3.25 [ 0.14, 76.01 ]
Subtotal (95% CI) 23 25 31.1 % 3.25 [ 0.14, 76.01 ]
Total events: 1 (antibiotics), 0 (placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Total (95% CI) 65 62 100.0 % 1.62 [ 0.23, 11.56 ]
Total events: 2 (antibiotics), 1 (placebo)
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotic Favours placebo
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Analysis 1.7. Comparison 1 Antibiotics (classes) versus placebo, Outcome 7 Bacteriuria (with pre-biopsy
enema).
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 7 Bacteriuria (with pre-biopsy enema)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Isen 1999a 2/42 6/23 13.2 % 0.18 [ 0.04, 0.83 ]
Kapoor 1998 7/241 21/242 35.7 % 0.33 [ 0.14, 0.77 ]
Tekdogan 2006 2/40 3/40 5.1 % 0.67 [ 0.12, 3.78 ]
Subtotal (95% CI) 323 305 54.0 % 0.33 [ 0.17, 0.64 ]
Total events: 11 (Antibiotics), 30 (Placebo)
Heterogeneity: Chi2 = 1.22, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
2 Sulfonamides
Isen 1999b 3/45 6/23 13.5 % 0.26 [ 0.07, 0.93 ]
Subtotal (95% CI) 45 23 13.5 % 0.26 [ 0.07, 0.93 ]
Total events: 3 (Antibiotics), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
3 Other classes of antibiotics
Brown 1981 1/11 4/9 7.5 % 0.20 [ 0.03, 1.52 ]
Crawford 1982 2/23 9/25 14.7 % 0.24 [ 0.06, 1.00 ]
Melekos 1990 1/25 5/16 10.4 % 0.13 [ 0.02, 1.00 ]
Subtotal (95% CI) 59 50 32.5 % 0.20 [ 0.07, 0.54 ]
Total events: 4 (Antibiotics), 18 (Placebo)
Heterogeneity: Chi2 = 0.25, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.18 (P = 0.0015)
Total (95% CI) 427 378 100.0 % 0.28 [ 0.17, 0.46 ]
Total events: 18 (Antibiotics), 54 (Placebo)
Heterogeneity: Chi2 = 2.15, df = 6 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 4.97 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
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Analysis 1.8. Comparison 1 Antibiotics (classes) versus placebo, Outcome 8 Bacteremia (with pre-biopsy
enema).
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 8 Bacteremia (with pre-biopsy enema)
Study or subgroup Antibiotics Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Aron 2000a 0/79 2/75 12.1 % 0.19 [ 0.01, 3.89 ]
Aron 2000b 1/77 2/75 9.5 % 0.49 [ 0.05, 5.26 ]
Subtotal (95% CI) 156 150 21.6 % 0.32 [ 0.05, 2.01 ]
Total events: 1 (Antibiotics), 4 (Placebo)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Other classes of antibiotics
Brown 1981 2/11 5/9 25.9 % 0.33 [ 0.08, 1.30 ]
Crawford 1982 5/23 4/25 18.0 % 1.36 [ 0.41, 4.45 ]
Melekos 1990 1/25 6/16 34.4 % 0.11 [ 0.01, 0.81 ]
Subtotal (95% CI) 59 50 78.4 % 0.47 [ 0.22, 0.98 ]
Total events: 8 (Antibiotics), 15 (Placebo)
Heterogeneity: Chi2 = 5.41, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 215 200 100.0 % 0.44 [ 0.22, 0.87 ]
Total events: 9 (Antibiotics), 19 (Placebo)
Heterogeneity: Chi2 = 5.85, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours placebo
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Analysis 1.9. Comparison 1 Antibiotics (classes) versus placebo, Outcome 9 Fever (with pre-biopsy enema).
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 1 Antibiotics (classes) versus placebo
Outcome: 9 Fever (with pre-biopsy enema)
Study or subgroup antibiotics placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Quinolones
Aron 2000a 2/79 5/75 12.7 % 0.38 [ 0.08, 1.90 ]
Aron 2000b 2/77 5/75 12.6 % 0.39 [ 0.08, 1.95 ]
Tekdogan 2006 3/40 2/40 5.0 % 1.50 [ 0.26, 8.50 ]
Yang 2001a 1/64 3/62 7.6 % 0.32 [ 0.03, 3.02 ]
Yang 2001b 1/66 3/62 7.7 % 0.31 [ 0.03, 2.93 ]
Subtotal (95% CI) 326 314 45.5 % 0.48 [ 0.22, 1.06 ]
Total events: 9 (antibiotics), 18 (placebo)
Heterogeneity: Chi2 = 2.06, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 Other classes of antibiotics
Brown 1981 0/11 3/9 9.5 % 0.12 [ 0.01, 2.04 ]
Crawford 1982 4/23 12/25 28.5 % 0.36 [ 0.14, 0.97 ]
Melekos 1990 0/25 5/16 16.5 % 0.06 [ 0.00, 1.01 ]
Subtotal (95% CI) 59 50 54.5 % 0.23 [ 0.10, 0.54 ]
Total events: 4 (antibiotics), 20 (placebo)
Heterogeneity: Chi2 = 1.92, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00074)
Total (95% CI) 385 364 100.0 % 0.34 [ 0.20, 0.61 ]
Total events: 13 (antibiotics), 38 (placebo)
Heterogeneity: Chi2 = 4.84, df = 7 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 3.67 (P = 0.00024)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours experimental Favours control
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Analysis 2.1. Comparison 2 Antibiotics versus enema, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 2 Antibiotics versus enema
Outcome: 1 Bacteriuria
Study or subgroup antibiotics enema Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brown 1981 2/10 1/10 19.3 % 2.00 [ 0.21, 18.69 ]
Melekos 1990 2/22 2/18 42.5 % 0.82 [ 0.13, 5.25 ]
Tekdogan 2006 5/39 2/40 38.2 % 2.56 [ 0.53, 12.44 ]
Total (95% CI) 71 68 100.0 % 1.71 [ 0.61, 4.79 ]
Total events: 9 (antibiotics), 5 (enema)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours enema
Analysis 2.2. Comparison 2 Antibiotics versus enema, Outcome 2 Bacteremia.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 2 Antibiotics versus enema
Outcome: 2 Bacteremia








Brown 1981 8/10 2/10 52.8 % 4.00 [ 1.11, 14.35 ]
Melekos 1990 3/22 3/18 47.2 % 0.82 [ 0.19, 3.57 ]
Total (95% CI) 32 28 100.0 % 1.89 [ 0.40, 8.93 ]
Total events: 11 (Antibiotics), 5 (Enema)
Heterogeneity: Tau2 = 0.76; Chi2 = 2.54, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.80 (P = 0.42)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours enema
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Analysis 2.3. Comparison 2 Antibiotics versus enema, Outcome 3 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 2 Antibiotics versus enema
Outcome: 3 Fever








Brown 1981 5/10 1/10 25.9 % 5.00 [ 0.70, 35.50 ]
Freitas 1999 0/30 10/28 19.4 % 0.04 [ 0.00, 0.73 ]
Melekos 1990 2/22 2/18 26.8 % 0.82 [ 0.13, 5.25 ]
Tekdogan 2006 3/39 2/40 27.9 % 1.54 [ 0.27, 8.71 ]
Total (95% CI) 101 96 100.0 % 0.89 [ 0.16, 5.05 ]
Total events: 10 (Antibiotics), 15 (Enema)
Heterogeneity: Tau2 = 2.04; Chi2 = 8.75, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.13 (P = 0.89)
0.001 0.01 0.1 1 10 100 1000
Favours antibiotics Favours enema
Analysis 3.1. Comparison 3 Antibiotics versus antibiotics + enema, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 3 Antibiotics versus antibiotics + enema
Outcome: 1 Bacteriuria
Study or subgroup Antbiotic + enema Antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brown 1981 1/11 2/10 22.6 % 0.45 [ 0.05, 4.28 ]
Melekos 1990 1/25 2/22 22.9 % 0.44 [ 0.04, 4.53 ]
Tekdogan 2006 2/40 5/39 54.5 % 0.39 [ 0.08, 1.89 ]
Total (95% CI) 76 71 100.0 % 0.42 [ 0.13, 1.29 ]
Total events: 4 (Antbiotic + enema), 9 (Antibiotics)
Heterogeneity: Chi2 = 0.01, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
0.001 0.01 0.1 1 10 100 1000
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Analysis 3.2. Comparison 3 Antibiotics versus antibiotics + enema, Outcome 2 Bacteremia.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 3 Antibiotics versus antibiotics + enema
Outcome: 2 Bacteremia
Study or subgroup Antbiotic + Enema Antibiotic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brown 1981 2/11 8/10 72.4 % 0.23 [ 0.06, 0.83 ]
Melekos 1990 1/25 3/22 27.6 % 0.29 [ 0.03, 2.62 ]
Total (95% CI) 36 32 100.0 % 0.25 [ 0.08, 0.75 ]
Total events: 3 (Antbiotic + Enema), 11 (Antibiotic)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
0.001 0.01 0.1 1 10 100 1000
Favours ATB + enema Favours ATB
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Analysis 3.3. Comparison 3 Antibiotics versus antibiotics + enema, Outcome 3 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 3 Antibiotics versus antibiotics + enema
Outcome: 3 Fever
Study or subgroup Antbiotic + enema Antibiotics Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brown 1981 0/11 5/10 48.0 % 0.08 [ 0.01, 1.34 ]
Freitas 1999 2/32 0/30 4.3 % 4.70 [ 0.23, 94.01 ]
Melekos 1990 0/25 2/22 22.2 % 0.18 [ 0.01, 3.50 ]
Tekdogan 2006 3/40 3/39 25.4 % 0.98 [ 0.21, 4.54 ]
Total (95% CI) 108 101 100.0 % 0.53 [ 0.21, 1.34 ]
Total events: 5 (Antbiotic + enema), 10 (Antibiotics)
Heterogeneity: Chi2 = 4.86, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 1.34 (P = 0.18)
0.001 0.01 0.1 1 10 100 1000
Favours ATB + enema Favours ATB
Analysis 4.1. Comparison 4 Short-course versus long-course treatment, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 4 Short-course versus long-course treatment
Outcome: 1 Bacteriuria
Study or subgroup Short-course Long-course Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Briffaux 2009 6/139 6/149 37.0 % 1.07 [ 0.35, 3.25 ]
Petteffi 2002 15/50 4/54 24.6 % 4.05 [ 1.44, 11.39 ]
Schaeffer 2007 11/239 6/238 38.4 % 1.83 [ 0.69, 4.86 ]
Total (95% CI) 428 441 100.0 % 2.09 [ 1.17, 3.73 ]
Total events: 32 (Short-course), 16 (Long-course)
Heterogeneity: Chi2 = 3.04, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 2.51 (P = 0.012)
0.001 0.01 0.1 1 10 100 1000
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Analysis 4.2. Comparison 4 Short-course versus long-course treatment, Outcome 2 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 4 Short-course versus long-course treatment
Outcome: 2 Fever
Study or subgroup Short-course Long-course Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aron 2000a 2/79 2/77 45.2 % 0.97 [ 0.14, 6.75 ]
Cam 2008 1/130 0/131 11.1 % 3.02 [ 0.12, 73.53 ]
Petteffi 2002 8/51 1/54 21.7 % 8.47 [ 1.10, 65.36 ]
Yang 2001a 1/64 1/66 22.0 % 1.03 [ 0.07, 16.14 ]
Total (95% CI) 324 328 100.0 % 2.84 [ 0.99, 8.16 ]
Total events: 12 (Short-course), 4 (Long-course)
Heterogeneity: Chi2 = 2.80, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
0.001 0.01 0.1 1 10 100 1000
Favours short-course Favours long-course
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Analysis 4.3. Comparison 4 Short-course versus long-course treatment, Outcome 3 UTI.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 4 Short-course versus long-course treatment
Outcome: 3 UTI
Study or subgroup Short-course Long-course Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aron 2000a 4/79 6/77 40.4 % 0.65 [ 0.19, 2.21 ]
Briffaux 2009 1/139 1/149 6.4 % 1.07 [ 0.07, 16.97 ]
Cam 2008 2/130 2/131 13.3 % 1.01 [ 0.14, 7.05 ]
Schaeffer 2007 13/239 5/238 33.3 % 2.59 [ 0.94, 7.15 ]
Yang 2001a 1/64 1/66 6.6 % 1.03 [ 0.07, 16.14 ]
Total (95% CI) 651 661 100.0 % 1.40 [ 0.73, 2.68 ]
Total events: 21 (Short-course), 15 (Long-course)
Heterogeneity: Chi2 = 3.11, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.31)
0.001 0.01 0.1 1 10 100 1000
Favours short-course Favours long-course
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Analysis 4.4. Comparison 4 Short-course versus long-course treatment, Outcome 4 Hospitalization.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 4 Short-course versus long-course treatment
Outcome: 4 Hospitalization
Study or subgroup Short-course Long-course Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cam 2008 1/130 0/131 50.6 % 3.02 [ 0.12, 73.53 ]
Petteffi 2002 2/51 0/54 49.4 % 5.29 [ 0.26, 107.57 ]
Total (95% CI) 181 185 100.0 % 4.14 [ 0.47, 36.46 ]
Total events: 3 (Short-course), 0 (Long-course)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours short-course Favours long-course
Analysis 5.1. Comparison 5 Single versus multiple dose, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 5 Single versus multiple dose
Outcome: 1 Bacteriuria
Study or subgroup Single dose Multiple dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bates 1998 6/37 4/38 20.1 % 1.54 [ 0.47, 5.02 ]
Briffaux 2009 6/139 6/149 29.6 % 1.07 [ 0.35, 3.25 ]
Petteffi 2002 15/50 4/54 19.6 % 4.05 [ 1.44, 11.39 ]
Schaeffer 2007 11/239 6/238 30.7 % 1.83 [ 0.69, 4.86 ]
Total (95% CI) 465 479 100.0 % 1.98 [ 1.18, 3.33 ]
Total events: 38 (Single dose), 20 (Multiple dose)
Heterogeneity: Chi2 = 3.22, df = 3 (P = 0.36); I2 =7%
Test for overall effect: Z = 2.59 (P = 0.0097)
0.001 0.01 0.1 1 10 100 1000
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Analysis 5.2. Comparison 5 Single versus multiple dose, Outcome 2 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 5 Single versus multiple dose
Outcome: 2 Fever
Study or subgroup Single dose Multiple dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aron 2000a 2/79 2/77 45.2 % 0.97 [ 0.14, 6.75 ]
Cam 2008 1/130 0/131 11.1 % 3.02 [ 0.12, 73.53 ]
Petteffi 2002 8/51 1/54 21.7 % 8.47 [ 1.10, 65.36 ]
Yang 2001a 1/64 1/66 22.0 % 1.03 [ 0.07, 16.14 ]
Total (95% CI) 324 328 100.0 % 2.84 [ 0.99, 8.16 ]
Total events: 12 (Single dose), 4 (Multiple dose)
Heterogeneity: Chi2 = 2.80, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.053)
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Analysis 5.3. Comparison 5 Single versus multiple dose, Outcome 3 UTI.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 5 Single versus multiple dose
Outcome: 3 UTI
Study or subgroup Single dose Multiple dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Aron 2000a 4/79 6/77 40.4 % 0.65 [ 0.19, 2.21 ]
Briffaux 2009 1/139 1/149 6.4 % 1.07 [ 0.07, 16.97 ]
Cam 2008 2/130 2/131 13.3 % 1.01 [ 0.14, 7.05 ]
Schaeffer 2007 13/239 5/238 33.3 % 2.59 [ 0.94, 7.15 ]
Yang 2001a 1/64 1/66 6.6 % 1.03 [ 0.07, 16.14 ]
Total (95% CI) 651 661 100.0 % 1.40 [ 0.73, 2.68 ]
Total events: 21 (Single dose), 15 (Multiple dose)
Heterogeneity: Chi2 = 3.11, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.31)
0.001 0.01 0.1 1 10 100 1000
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Analysis 5.4. Comparison 5 Single versus multiple dose, Outcome 4 Hospitalization.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 5 Single versus multiple dose
Outcome: 4 Hospitalization
Study or subgroup Single dose Multiple dose Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bates 1998 2/37 1/38 50.1 % 2.05 [ 0.19, 21.70 ]
Cam 2008 1/130 0/131 25.3 % 3.02 [ 0.12, 73.53 ]
Petteffi 2002 2/51 0/54 24.7 % 5.29 [ 0.26, 107.57 ]
Total (95% CI) 218 223 100.0 % 3.10 [ 0.64, 15.06 ]
Total events: 5 (Single dose), 1 (Multiple dose)
Heterogeneity: Chi2 = 0.24, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 6.1. Comparison 6 Quinolones versus other classes of antibiotics, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 6 Quinolones versus other classes of antibiotics
Outcome: 1 Bacteriuria
Study or subgroup Other ATB Quinolones Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Sulfonamides
Isen 1999a 3/45 2/42 39.8 % 1.40 [ 0.25, 7.97 ]
Subtotal (95% CI) 45 42 39.8 % 1.40 [ 0.25, 7.97 ]
Total events: 3 (Other ATB), 2 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
2 Piperacillin Tazobactam
Cormio 2002 2/72 3/66 60.2 % 0.61 [ 0.11, 3.54 ]
Subtotal (95% CI) 72 66 60.2 % 0.61 [ 0.11, 3.54 ]
Total events: 2 (Other ATB), 3 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 117 108 100.0 % 0.93 [ 0.28, 3.10 ]
Total events: 5 (Other ATB), 5 (Quinolones)
Heterogeneity: Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
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Analysis 6.2. Comparison 6 Quinolones versus other classes of antibiotics, Outcome 2 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 6 Quinolones versus other classes of antibiotics
Outcome: 2 Fever
Study or subgroup Other ATB Quinolones Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Piperacillin Tazobactam
Cormio 2002 0/72 1/66 60.2 % 0.31 [ 0.01, 7.38 ]
Subtotal (95% CI) 72 66 60.2 % 0.31 [ 0.01, 7.38 ]
Total events: 0 (Other ATB), 1 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
2 Ceftriaxone
Cam 2008 1/139 1/130 39.8 % 0.94 [ 0.06, 14.80 ]
Subtotal (95% CI) 139 130 39.8 % 0.94 [ 0.06, 14.80 ]
Total events: 1 (Other ATB), 1 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 211 196 100.0 % 0.56 [ 0.07, 4.16 ]
Total events: 1 (Other ATB), 2 (Quinolones)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
0.001 0.01 0.1 1 10 100 1000
Favours other ATB Favours quinolones
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Analysis 6.3. Comparison 6 Quinolones versus other classes of antibiotics, Outcome 3 UTI.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 6 Quinolones versus other classes of antibiotics
Outcome: 3 UTI
Study or subgroup other ATB Quinolones Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Piperacillin Tazobactam
Cormio 2002 0/72 2/66 55.8 % 0.18 [ 0.01, 3.75 ]
Subtotal (95% CI) 72 66 55.8 % 0.18 [ 0.01, 3.75 ]
Total events: 0 (other ATB), 2 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
2 Ceftriaxone
Cam 2008 3/139 2/130 44.2 % 1.40 [ 0.24, 8.26 ]
Subtotal (95% CI) 139 130 44.2 % 1.40 [ 0.24, 8.26 ]
Total events: 3 (other ATB), 2 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 211 196 100.0 % 0.72 [ 0.18, 2.88 ]
Total events: 3 (other ATB), 4 (Quinolones)
Heterogeneity: Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 0.46 (P = 0.65)
0.001 0.01 0.1 1 10 100 1000
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Analysis 6.4. Comparison 6 Quinolones versus other classes of antibiotics, Outcome 4 Hospitalization.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 6 Quinolones versus other classes of antibiotics
Outcome: 4 Hospitalization
Study or subgroup Other ATB Quinolones Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Ceftriaxone
Cam 2008 1/139 1/130 39.8 % 0.94 [ 0.06, 14.80 ]
Subtotal (95% CI) 139 130 39.8 % 0.94 [ 0.06, 14.80 ]
Total events: 1 (Other ATB), 1 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 Piperacillin Tazobactam
Cormio 2002 0/72 1/66 60.2 % 0.31 [ 0.01, 7.38 ]
Subtotal (95% CI) 72 66 60.2 % 0.31 [ 0.01, 7.38 ]
Total events: 0 (Other ATB), 1 (Quinolones)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 211 196 100.0 % 0.56 [ 0.07, 4.16 ]
Total events: 1 (Other ATB), 2 (Quinolones)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
0.001 0.01 0.1 1 10 100 1000
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Analysis 7.1. Comparison 7 Sulfonamides versus other antibiotics, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 7 Sulfonamides versus other antibiotics
Outcome: 1 Bacteriuria









Shivde 2002 5/53 1/62 30.9 % 5.85 [ 0.71, 48.51 ]
Subtotal (95% CI) 53 62 30.9 % 5.85 [ 0.71, 48.51 ]
Total events: 5 (Other Antibiotics), 1 (Sulfa)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
2 Netilmicin-metronidazole
Fong 1991 8/47 1/54 32.0 % 9.19 [ 1.19, 70.81 ]
Subtotal (95% CI) 47 54 32.0 % 9.19 [ 1.19, 70.81 ]
Total events: 8 (Other Antibiotics), 1 (Sulfa)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
3 Quinolone
Isen 1999a 2/42 3/45 37.0 % 0.71 [ 0.13, 4.07 ]
Subtotal (95% CI) 42 45 37.0 % 0.71 [ 0.13, 4.07 ]
Total events: 2 (Other Antibiotics), 3 (Sulfa)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 142 161 100.0 % 3.10 [ 0.60, 16.13 ]
Total events: 15 (Other Antibiotics), 5 (Sulfa)
Heterogeneity: Tau2 = 1.12; Chi2 = 4.25, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 1.35 (P = 0.18)
0.001 0.01 0.1 1 10 100 1000
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Analysis 8.1. Comparison 8 Piperacillin tazobactam versus other antibiotics, Outcome 1 Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 8 Piperacillin tazobactam versus other antibiotics
Outcome: 1 Bacteriuria
Study or subgroup Other ATB Piper/tazob Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cefuroxime
Brewster 1995 2/55 3/54 61.3 % 0.65 [ 0.11, 3.76 ]
Subtotal (95% CI) 55 54 61.3 % 0.65 [ 0.11, 3.76 ]
Total events: 2 (Other ATB), 3 (Piper/tazob)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.63)
2 Ciprofloxacin
Cormio 2002 3/66 2/72 38.7 % 1.64 [ 0.28, 9.49 ]
Subtotal (95% CI) 66 72 38.7 % 1.64 [ 0.28, 9.49 ]
Total events: 3 (Other ATB), 2 (Piper/tazob)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 121 126 100.0 % 1.03 [ 0.31, 3.46 ]
Total events: 5 (Other ATB), 5 (Piper/tazob)
Heterogeneity: Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.96)
0.001 0.01 0.1 1 10 100 1000
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Analysis 8.2. Comparison 8 Piperacillin tazobactam versus other antibiotics, Outcome 2 UTI.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 8 Piperacillin tazobactam versus other antibiotics
Outcome: 2 UTI
Study or subgroup Other ATB Piper/tazob Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cefuroxime
Brewster 1995 3/55 5/54 91.3 % 0.59 [ 0.15, 2.34 ]
Subtotal (95% CI) 55 54 91.3 % 0.59 [ 0.15, 2.34 ]
Total events: 3 (Other ATB), 5 (Piper/tazob)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
2 Ciprofloxacin
Cormio 2002 2/66 0/72 8.7 % 5.45 [ 0.27, 111.43 ]
Subtotal (95% CI) 66 72 8.7 % 5.45 [ 0.27, 111.43 ]
Total events: 2 (Other ATB), 0 (Piper/tazob)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
Total (95% CI) 121 126 100.0 % 1.01 [ 0.32, 3.15 ]
Total events: 5 (Other ATB), 5 (Piper/tazob)
Heterogeneity: Chi2 = 1.78, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.02 (P = 0.99)
0.001 0.01 0.1 1 10 100 1000
Favours other ATB Favours piper/tazob
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Analysis 8.3. Comparison 8 Piperacillin tazobactam versus other antibiotics, Outcome 3 Sepsis.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 8 Piperacillin tazobactam versus other antibiotics
Outcome: 3 Sepsis
Study or subgroup Other ATB Piper/tazob Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cefuroxime
Brewster 1995 1/55 0/54 51.3 % 2.95 [ 0.12, 70.77 ]
Subtotal (95% CI) 55 54 51.3 % 2.95 [ 0.12, 70.77 ]
Total events: 1 (Other ATB), 0 (Piper/tazob)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
2 Ciprofloxacin
Cormio 2002 1/66 0/72 48.7 % 3.27 [ 0.14, 78.87 ]
Subtotal (95% CI) 66 72 48.7 % 3.27 [ 0.14, 78.87 ]
Total events: 1 (Other ATB), 0 (Piper/tazob)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 121 126 100.0 % 3.10 [ 0.33, 29.40 ]
Total events: 2 (Other ATB), 0 (Piper/tazob)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
0.001 0.01 0.1 1 10 100 1000
Favours other ATB Favours piper/tazob
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Analysis 8.4. Comparison 8 Piperacillin tazobactam versus other antibiotics, Outcome 4 Hospitalization.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 8 Piperacillin tazobactam versus other antibiotics
Outcome: 4 Hospitalization
Study or subgroup Other ATB Piper/tazo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cefuroxime
Brewster 1995 1/55 0/54 51.3 % 2.95 [ 0.12, 70.77 ]
Subtotal (95% CI) 55 54 51.3 % 2.95 [ 0.12, 70.77 ]
Total events: 1 (Other ATB), 0 (Piper/tazo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
2 Ciprofloxacin
Cormio 2002 1/66 0/72 48.7 % 3.27 [ 0.14, 78.87 ]
Subtotal (95% CI) 66 72 48.7 % 3.27 [ 0.14, 78.87 ]
Total events: 1 (Other ATB), 0 (Piper/tazo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 121 126 100.0 % 3.10 [ 0.33, 29.40 ]
Total events: 2 (Other ATB), 0 (Piper/tazo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
0.001 0.01 0.1 1 10 100 1000
Favours other ATB Favours piper/tazob
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Analysis 9.1. Comparison 9 Oral versus systemic antibiotic administration (IM or IV), Outcome 1
Bacteriuria.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 9 Oral versus systemic antibiotic administration (IM or IV)
Outcome: 1 Bacteriuria








Cormio 2002 3/66 2/72 36.4 % 1.64 [ 0.28, 9.49 ]
Fong 1991 1/54 8/47 32.3 % 0.11 [ 0.01, 0.84 ]
Shivde 2002 1/62 5/53 31.3 % 0.17 [ 0.02, 1.42 ]
Total (95% CI) 182 172 100.0 % 0.34 [ 0.06, 1.93 ]
Total events: 5 (Oral), 15 (Systemic)
Heterogeneity: Tau2 = 1.38; Chi2 = 4.74, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.22 (P = 0.22)
0.001 0.01 0.1 1 10 100 1000
Favours oral Favours systemic
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Analysis 9.2. Comparison 9 Oral versus systemic antibiotic administration (IM or IV), Outcome 2 Fever.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 9 Oral versus systemic antibiotic administration (IM or IV)
Outcome: 2 Fever
Study or subgroup Oral Systemic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cam 2008 1/130 1/139 1.07 [ 0.07, 16.92 ]
Cormio 2002 1/66 0/72 3.27 [ 0.14, 78.87 ]
Shivde 2002 0/62 0/53 0.0 [ 0.0, 0.0 ]
Total (95% CI) 258 264 1.80 [ 0.24, 13.45 ]
Total events: 2 (Oral), 1 (Systemic)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours oral Favours systemic
Analysis 9.3. Comparison 9 Oral versus systemic antibiotic administration (IM or IV), Outcome 3 UTI.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 9 Oral versus systemic antibiotic administration (IM or IV)
Outcome: 3 UTI
Study or subgroup Oral Systemic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cam 2008 2/130 3/139 47.9 % 0.71 [ 0.12, 4.20 ]
Cormio 2002 2/66 0/72 7.9 % 5.45 [ 0.27, 111.43 ]
Fong 1991 0/54 2/47 44.1 % 0.17 [ 0.01, 3.55 ]
Total (95% CI) 250 258 100.0 % 0.85 [ 0.27, 2.70 ]
Total events: 4 (Oral), 5 (Systemic)
Heterogeneity: Chi2 = 2.55, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours oral Favours systemic
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Analysis 9.4. Comparison 9 Oral versus systemic antibiotic administration (IM or IV), Outcome 4
Hospitalization.
Review: Antibiotic prophylaxis for transrectal prostate biopsy
Comparison: 9 Oral versus systemic antibiotic administration (IM or IV)
Outcome: 4 Hospitalization
Study or subgroup Oral Systemic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cam 2008 1/130 1/139 66.9 % 1.07 [ 0.07, 16.92 ]
Cormio 2002 1/66 0/72 33.1 % 3.27 [ 0.14, 78.87 ]
Total (95% CI) 196 211 100.0 % 1.80 [ 0.24, 13.45 ]
Total events: 2 (Oral), 1 (Systemic)
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours oral Favours systemic
A D D I T I O N A L T A B L E S
Table 1. Outcomes analysed in each included study
Study Bacteriuria Bacteremia Fever UTI Sepsis Mortality Hospitalization Adverse events
Aron 2000 X X X
Bates 1998 X X X
Brewster
1995




Brown 1981 X X X
108Antibiotic prophylaxis for transrectal prostate biopsy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Outcomes analysed in each included study (Continued)
Cam 2008 X X X
Cormio
2002
X X X X X
Crawford
1982
X X X X X
Fong 1991 X X X
Freitas 1999 X X X X X
Isen 1999 X X X
Kapoor
1998

















Yang 2001 X X
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Table 2. Included studies in each category of comparison (Continued)
Crawford
1982





Petteffi 2002 Cam 2008
Kapoor 1998 Briffaux 2008 Schaeffer
2007
Isen 1999 Cam 2008 Briffaux 2008




W H A T ’ S N E W
Last assessed as up-to-date: 30 August 2010.
Date Event Description
30 September 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 5, 2011
Date Event Description
3 April 2007 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
ELZ: trial selection, quality assessment, data extraction, data entry, data analysis, writing of protocol and review
OACC: trial selection, quality assessment, data extraction, data entry, data analysis, writing of protocol, revision of protocol and review
NRN Jr: data analysis, writing of protocol, resolution of disagreements, revision of protocol and review
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• None, Not specified.
External sources
• None, Not specified.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibiotic Prophylaxis [∗methods]; Bacteremia [prevention & control]; Bacterial Infections [∗prevention & control]; Bacteriuria [pre-
vention & control]; Biopsy, Needle [∗adverse effects; methods]; Hospitalization [statistics & numerical data]; Prostate [∗pathology];
Prostatic Neoplasms [pathology]; Urinary Tract Infections [prevention & control]
MeSH check words
Humans; Male
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